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ABSTRACT 
 
 
 
Calcium/Calmodulin-Dependent Protein Kinase IIβ (CaMKIIβ): A Regulator of 
Oligodendrocyte Maturation and Myelination  
 
 
By Christopher Thomas Waggener 
 
 
A dissertation submitted in partial fulfillment of the requirements for the degree of 
Doctor of Philosophy at Virginia Commonwealth University 
 
Virginia Commonwealth University  
 
 
Advisor: Babette Fuss, Ph.D., Professor, Department of Anatomy and 
Neurobiology  
 
 
Oligodendrocytes are cells located in the central nervous system (CNS) 
that are responsible for the production of the lipid rich membrane, myelin. Myelin 
and the process of making and wrapping myelin around an axon (also known as 
myelination) are critical for normal development since they ensure proper signal 
conduction in the vertebrate CNS. The loss or damage of this myelin, which is 
typically associated with the demyelinating disease multiple sclerosis (MS), is 
associated with improper axonal protection along with disrupted nerve signaling 
which can lead to a variety of different debilitating phenotypic responses. It has 
been shown that there are MS lesions in which oligodendrocyte progenitors are 
present. However, while these cells are thought to possess the intrinsic ability to 
myelinate, they do not efficiently mature and/or repair the myelin sheath within 
the MS lesion. The reasons for this block in differentiation are currently not fully 
understood. A critical and thorough understanding of oligodendrocyte 
  
x 
development provides the foundation needed for future research to potentially 
provide therapeutic targets for stimulating proper maturation and efficient 
remyelination from the oligodendrocyte progenitors that are present within the 
MS brain.  
In the search for regulators of oligodendrocyte development and potential 
therapeutic targets, the data generated as part of my thesis provided evidence 
that CaMKII (more specifically CaMKIIβ) is a regulator of oligodendrocyte 
myelination and maturation. Using pharmacological inhibitors or siRNA-mediated 
knockdown of this protein resulted in improper formation of the oligodendrocyte 
process network.  Interestingly, siRNA-mediated knockdown of CaMKIIβ 
appeared to play no noticeable role in the genetic regulation of specific 
oligodendrocyte developmental markers.  Furthermore, an overall reduction of 
the thickness of the compact myelin was observed in the ventral spinal cord of 
CaMKIIβ knockout mice.  These findings emphasize the importance of CaMKIIβ 
in oligodendrocyte myelination and maturation. 
To further investigate CaMKIIβ’s role in the regulation of CNS myelination, 
the effect of glutamate signaling on CaMKIIβ and in particular its actin binding 
site were assessed. These data showed that signaling via glutamate transporters 
promote an increase of process network in oligodendrocytes. This effect was 
associated with a transient increase in intracellular calcium concentration and a 
change in the phosphorylation of at least one serine residue present within 
CaMKIIβ’s actin binding site. Changes in phosphorylation of CaMKIIβ’s actin 
binding site suggested that CaMKIIβ detaches from filamentous F-actin and 
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allows for remodeling of the oligodendrocyte’s actin cytoskeleton.  This was 
demonstrated by overexpressing CaMKIIβ actin binding mutant constructs to 
alter phosphorylation of serine residues to either always allow actin binding 
(CaMKIIβallA) or never allow actin binding (CaMKIIβallD).  The overexpression of 
CaMKIIβallD alone demonstrated a decrease in the process network of 
oligodendrocytes and inhibited the effect of glutamate on the process network.  In 
contrast, the overexpression of CaMKIIβallA and CaMKIIβWT alone showed normal 
process network formation along with a significant increase in the process 
network after stimulation of glutamate.  The above data strongly suggest that 
there is a significant relationship between sodium dependent glutamate 
transporters/CaMKIIβ activation and the oligodendrocyte cytoskeleton in the role 
of regulation of oligodendrocyte differentiation and CNS myelination.   
The data presented in this dissertation provides overwhelming evidence 
that CaMKIIβ plays a significant role in the proper formation of the 
oligodendrocyte complex process network and myelination.  CaMKIIβ’s 
relationship with glutamate and the actin cytoskeleton could lay the foundation for 
future research not only for the signaling of oligodendrocyte process formation 
and remyelination but also for future targets for MS therapies.
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CHAPTER 1 
Introduction to Oligodendrocyte Biology and CaMKIIβ 
 
 
Myelin and its functional significance 
 
The myelin membrane is the most prominent membrane structure in the 
vertebrate nervous system. Myelin is a lipid rich multilamellar membrane that 
surrounds axons in a segmental fashion.  Oligodendrocytes in the central 
nervous system and Schwann cells in the peripheral nervous system are the 
cells that are responsible for producing the myelin membrane. Myelin was 
originally named by Rudolf Virchow in the mid 1850’s (Baumann and Pham-Dinh, 
2001); however, oligodendrocytes were discovered by Rio Hortega almost 70 
years later in 1921(Helmut Kettenmann, 2005).  The myelin membrane is highly 
insulative and has a low water content.  Myelin has a unique segmental 
morphology that structurally allows for gaps in between the myelin segments. 
These gaps (also known as nodes of Ranvier) allow for fast and efficient 
propagation of nerve impulses called action potentials. This fast propagation of 
action potentials is due to a process named saltatory conduction, which allows 
for faster conductions over long distances and reliable signal transfer in smaller 
diameter axons (Baumann and Pham-Dinh, 2001).  
 Myelin was one of the later structures of the nervous system to evolve 
(Baumann and Pham-Dinh, 2001, Hartline and Colman, 2007). Evolutionary need 
for fast conduction of nerve fibers stems from the demand for animals to make 
quick decisions to avoid prey (Hartline and Colman, 2007). There are certain 
physiological properties that allow for increased speed of conduction. Increasing 
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the size of the axon decreases the overall resistance of the electrical signal and 
allows for faster conduction. This option is not practical in mammals, as nerve 
fibers would have to be extremely large in proportion to the their body size and 
space requirements for the type of conduction speed that mammals require.  
Insulating the axon with a thick lipid myelin membrane increases the resistance 
of the electrical field in the longitudinal axis of the axon from the outside of the 
membrane and decreases the transverse capacitance between the inside and 
the outside nerve fiber (Hartline and Colman, 2007). By insulating the axon with 
myelin, sodium channels are clustered at the nodes of Ranvier while there are no 
action potentials generated along the segmental myelin sheath (internode). The 
clusters of sodium channels combined with the insulation of the myelin sheath 
greatly increase the conduction velocity of action potentials while keeping the 
axon diameter reasonably small (Baumann and Pham-Dinh, 2001, Helmut 
Kettenmann, 2005). 
 The importance of myelin has become evident not only in pathologies (or 
experimental paradigms) where it is not formed properly during development but 
also under conditions in which it is destructed such as in the demyelinating 
disease multiple sclerosis (MS) (Baumann and Pham-Dinh, 2001). 
  
Multiple sclerosis (MS), the major demyelinating disease in humans 
Understanding oligodendrocyte development is essential to gain more 
knowledge not only in the basic developmental process of myelination but also to 
treat diseases and disorders that affect oligodendrocytes and/or myelin. One of 
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the most studied demyelinating diseases is multiple sclerosis (MS). Currently 
there is no cure for the disease and no treatment for stimulating remyelination by 
oligodendrocytes and/or their progenitors.  MS affects 2.1 million people 
worldwide (Multiple Sclerosis Society 2013). There are over 400,000 diagnosed 
cases in the United States alone with more than 200 new cases diagnosed a 
day. The most common ages of diagnosis of MS is between the ages of 20 to 50 
years of age. However, over the past few years, there has been an increase in 
the diagnosis of pediatric cases (Fox et al., 2006b, Yeh et al., 2009). MS 
presents as single or multiple lesions anywhere in the brain and results in 
symptoms that can range from a single neurological deficit to multiple 
neurological deficits (Fox et al., 2006b).  
The cause of MS is still unknown; however, there are genetic and 
environmental factors that are thought to play a role in the development of the 
disease (Hauser and Oksenberg, 2006). One of the current environmental factors 
that could contribute to the disease is a vitamin D deficiency. An epidemiological 
study showed that MS cases tend to occur less frequently in populations of 
people who live closer to the equator. Researchers theorize that people living 
closer to the equator tend to have more sun exposure than those living in colder 
climates farther away from the equator (Freedman et al., 2000).  
The genetic factors of MS are widely unknown and have not been strictly 
linked to heredity. However, an individual is much more at risk of developing MS 
than the general population if that individual has had a first-degree relative 
(parent or sibling) with MS . Furthermore, some researchers believe that 
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individuals are born with a genetic predisposition that makes them more sensitive 
to environmental agents that can cause the disease (Multiple Sclerosis Society 
2013). All in all, there are many theories for the environmental and genetic 
causes for MS but researchers have not been able to pinpoint specific reasons 
why people develop MS.  
MS is a complicated disease; currently there are 4 different disease 
courses with varying amounts of severity. The most common type of MS is 
relapsing-remitting with 85% of patients being diagnosed with this form of the 
disease. Relapsing-remitting MS is characterized by bouts of MS attacks with 
symptoms included but not limited to: sensory symptoms (numbness and 
tingling), motor symptoms (weakness and spasticity), coordination abnormalities, 
vision difficulties, bladder dysfunction, and fatigue; followed by periods of 
recovery (Fox et al., 2006b, Comabella and Martin, 2007).  The second form of 
the disease is primary progressive. This form of the disease has been 
characterized by slow but gradually progressive neurologic symptoms from the 
onset with no time points of recovery. The primary progressive type is seen in 
about 10% of the population with MS (Fox et al., 2006b). Secondary progressive 
is the third form of MS that is seen in about 50% of the MS population that first 
exhibits the relapsing-remitting form of MS (Fox et al., 2006b). Secondary 
progressive MS is characterized by a continuous worsening of neurological 
deficits with differing amounts of severity over time. Lastly the most rare form of 
MS is progressive relapsing. With only 5% occurrence in the population, 
progressive relapsing MS is characterized by steadily worsening disease from 
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the beginning but with clear bouts of more severe neurological symptoms. Times 
of remissions are seen by some but not all of the patients experiencing this form 
of MS (Multiple Sclerosis Society 2013). Therefore, classifying MS can be 
difficult, especially given the varying symptoms and degrees of severity 
(Comabella and Martin, 2007).  
Although the cause of MS is unknown, much progress has been made in 
understanding the pathology of MS. Since MS is classified as an autoimmune 
disease, inflammation is often associated with MS lesions and potentially plays a 
role in the damaging of oligodendrocytes. Whether or not the axon is affected by 
the inflammation or the physical loss of myelin is still under debate in the field. 
Current therapies are treating this inflammation and attenuating or lessening the 
relapsing portion of the disease. However, the loss of myelin and axonal damage 
still continues and is not treated by the current therapies on the market for MS 
patients.  
Because there are no current therapies to correct or aid in the 
remyelination of axons by oligodendrocytes in MS lesions, the focus of this 
dissertation is on understanding oligodendrocyte development and myelination. 
This information is important because it is believed that the repair of the myelin 
sheath follows the same concepts as the generation of the myelin sheath during 
normal development.  By researching oligodendrocyte development, researchers 
can identify oligodendrocytes found in MS lesions and use this information to 
target potential remyelination therapies. The oligodendrocytes in MS lesions are 
immature and lack the ability to remyelinate (Chang et al., 2002). The lack of 
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differentiation in oligodendrocytes present in the MS lesion leads to inhibition of 
proper remyelination.  This could be due to an altered local environment and 
altered signals (Chang et al., 2002,Colognato, 2011 #368, Lafrenaye and Fuss, 
2010). Although some of these cells remyelinate axons, this remyelination is 
insufficient (Goldschmidt et al., 2009, Bradl and Lassmann, 2010, Emery, 2010).  
Understanding oligodendrocyte development and myelination can provide 
a wealth of information that could lead to potential therapies to repair the 
damaged/absent myelin in MS and possibly also in other diseases displaying 
pathological features of demyelination (such as leukodystrophies, neuromyelitis 
optica, transverse myelitis, and optic neuritis) (Keyoung and Goldman, 2007, 
Goldman et al., 2012).  One option for a potential therapy is stem cell 
replacement. Exogenous stem cell transplantation studies have shown promising 
results. However, current research resulted in a shift towards pharmacologically-
based therapies.  Pharmacologically-based therapies target the endogenous 
regenerative processes of oligodendrocyte maturation and myelination.  This 
research has focused on the changes not only within the cell but also on changes 
within the environment around the cells to a younger more plastic environment to 
enhance remyelination. (Lindvall and Kokaia, 2006, Zawadzka et al., 2010, 
Ruckh et al., 2012, Stoffels et al., 2013). Studies have shown that by replacing 
macrophages and blood factors from younger animals into older animals that 
have demyelinating lesions, remyelination by the endogenous cells was achieved 
(Lindvall and Kokaia, 2006, Zawadzka et al., 2010, Ruckh et al., 2012, Stoffels et 
al., 2013). This result is significant because it shows that less plasticity in the 
 
 
 
 
 
7 
cells and local environment is observed in older animals.  These cells, however, 
have the innate ability to remyelinate if prompted by the new altered local 
environment around them. This research and other research into oligodendrocyte 
development are leading to a better understanding of the molecular mechanisms 
that promote oligodendrocyte differentiation during development that have the 
potential to reveal novel targets for designing remyelinating therapies. This 
research is also important because there are no current therapies that address 
the issue of remyelination available for patients today.  
 
Oligodendrocyte specification  
 Since the discovery of oligodendrocytes, their origins in the brain and spinal 
cord have been highly debated. Recent in vivo studies using transgenic mouse 
models to track the origins of oligodendrocytes have, for the most part, provided 
much insight into the origins of oligodendrocytes. The majority of this research 
has, however, focused on the spinal cord and only very recently has begun to 
explore the origins of oligodendrocytes in the brain (Richardson et al., 2006) 
 As the brain develops from its early embryonic form to its more mature 
form, it develops layers and zones of cell initiation and proliferation. These zones 
of development as well as all of the brain and spinal cord are of neuroectodermal 
origin. Each zone comprises and produces distinct cell types and cell 
morphologies (Pringle et al., 1996, Woodruff et al., 2001, Brazel et al., 2003, 
Marshall et al., 2003, Helmut Kettenmann, 2005, Richardson et al., 2006).  
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 Neurons and some astrocytes originate from the ventricular zone of the 
brain, which is the first cell proliferative area to develop.  The ventricular zone of 
the brain is a pseudostratified epithelial-like tissue that consists of 
neuroectodermal tissue (Helmut Kettenmann, 2005). During embryonic 
development, an area of tissue distal to the ventricular zone becomes highly 
proliferative and begins to thicken. This new proliferative area of the brain is 
known as the subventricular zone (Brazel et al., 2003). Since the cells within the 
ventricular zone lose their proliferative capability by birth (P0) in the mouse, the 
cells leave the ventricular zone and will eventually diminish into a thin wall of 
ependymal cells. In contrast, the subventricular zone remains actively 
proliferative early postnatally (Brazel et al., 2003). In the cortex, cortical 
progenitors follow a developmental sequence of neuronal development, then 
astrocyte development, and lastly oligodendrocyte development. The generation 
of each of these cell types occurs in a temporally distinct yet overlapping pattern 
(Spassky et al., 1998, Spassky et al., 2000, Sauvageot and Stiles, 2002). 
  From studies in the rodent system, oligodendrocyte progenitors are thought 
to be derived from discrete locations in the brain and spinal cord (Miller, 1996, 
Woodruff et al., 2001, Richardson et al., 2006). Research suggests that 
oligodendrocyte progenitor cells arise from the ventricular zone of the spinal cord 
and the subventricular zone of the developing brain (Privat and Leblond, 1972, 
Levison et al., 1993, Brazel et al., 2003, Marshall et al., 2003, Helmut 
Kettenmann, 2005, Baracskay et al., 2007). The majority of oligodendrocyte 
progenitor cells arise from this subventral region of the neuroaxis (Helmut 
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Kettenmann, 2005). Experiments conducted with rat spinal cords showed that 
initially most oligodendrocytes have a restricted subventral origination and only 
later are derived from more dorsal regions as well.  
 There are multiple areas along the ventral and dorsal axes of the spinal 
cord that produce oligodendrocyte progenitor cells at different time points. The 
so-called pMN (motor neuron progenitor) domain of the spinal cord is responsible 
for 85 percent of the oligodendrocyte production in the first wave of 
oligodendrocyte generations beginning around E12.5 (Richardson et al., 1988, 
Pringle and Richardson, 1993, Miller, 1996, Pringle et al., 1996, Woodruff et al., 
2001, Richardson et al., 2006). The second wave of oligodendrocyte production 
in the spinal cord is found to originate from more dorsal regions in the area of the 
dorsal progenitor domains 3-5 around E15 (Cai et al., 2005, Fogarty et al., 2005, 
Vallstedt et al., 2005, Emery, 2010). 
 Oligodendrocyte progenitor cells in the brain can be found in various 
regions of the subventricular zone (Levison and Goldman, 1993, Helmut 
Kettenmann, 2005). More specifically, oligodendrocytes originate from the medial 
and lateral ganglionic eminences (Woodruff et al., 2001, Brazel et al., 2003, de 
Castro and Bribian, 2005, Kessaris et al., 2006, Richardson et al., 2006). These 
eminence structures are thought to be transient and are only present during 
embryonic development. Data from transgenic fate mapping suggests that 
oligodendrocyte progenitor cells migrate from these subventricular structures to 
the cortex in several waves (Figure 1.1).  Oligodendrocyte progenitor cells of the 
first wave are first seen in the SVZ at E12.5 where they then migrate into the 
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cortex (Kessaris et al., 2006, Richardson et al., 2006).  Oligodendrocytes in and 
throughout the entire cortex are observed around E18 (Woodruff et al., 2001, 
Kessaris et al., 2006, Richardson et al., 2006). 
  The second wave of movement from the subventricular zone comes from 
the more dorsal region of the lateral and caudal ganglionic eminences (Woodruff 
et al., 2001, Brazel et al., 2003, Kessaris et al., 2006, Richardson et al., 2006). 
Before E18, the source of oligodendrocyte progenitor cells originate from more 
ventral locations. After E18, the contribution of ventral cells decreases and a 
second wave of more dorsal locations sends cells to the cortex (Woodruff et al., 
2001, Kessaris et al., 2006, Richardson et al., 2006). 
 The third wave of migration comes from the dorsolateral subventricular 
zone.  This zone can be identified through adulthood (Woodruff et al., 2001, 
Brazel et al., 2003, Kessaris et al., 2006, Richardson et al., 2006). The later 
migration from the dorsolateral subventricular zone starts at P2 of development 
(Levison and Goldman, 1993, Brazel et al., 2003). Thus, spatiotemporal 
oligodendrocyte specification initially begins in the ventral regions of the brain 
and spinal cord and then migrates to dorsal regions as development progresses 
(Cai et al., 2005, Fogarty et al., 2005, Vallstedt et al., 2005, Richardson et al., 
2006, Emery, 2010) (Figure 1.1).  
 From the areas of origin, oligodendrocyte progenitor cells migrate in a 
dorsal and lateral pattern in the brain and spinal cord (Levison and Goldman, 
1993, Cayre et al., 2009).  Dorsally migrating cells not only move in a 
dorsolateral pattern but also move radially as well, stopping in white matter areas 
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above their original location or moving through the white matter into the cortex 
(Cayre et al., 2009) (Figure 1.1).  
 Unlike developing neurons, oligodendrocyte progenitor cells still proliferate 
while undergoing the process of migration. Evidence from real time imaging of 
acute brain slices suggests that migration temporarily ceases when mitosis 
begins (Zerlin et al., 2004, Cayre et al., 2009). Temporarily stopping migration 
explains why oligodendrocyte progenitors can create clonal populations of cells 
that colonize multiple levels of white matter and cortex (Zerlin et al., 2004).  
 Interestingly, the above described ventral dorsal spatiotemporal 
oligodendrocyte progenitor cell specification is not seen in the chick embryo. 
Chick and quail grafting experiments show that all oligodendrocytes in the avian 
cortex are ventrally derived (Richardson et al., 2006). It seems to be that only the 
higher order animals are capable of dorsally derived oligodendrocytes 
progenitors.   
 As discussed above, oligodendrocyte progenitors arise from specific 
restricted locations and migrate in a controlled fashion throughout the central 
nervous system to populate future white matter areas of the brain.  
 
Oligodendrocyte differentiation – changes in gene expression  
As described above, oligodendrocyte progenitor cells are first specified in 
localized ventricular and subventricular zones in the spinal cord and brain. These 
cells then begin a radial dorsolateral migration pattern away from the highly 
proliferative zones of origination to populate the entire spinal cord and brain, 
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where they differentiate into mature myelinating oligodendrocytes. Specific cell 
markers (lipids, proteins, surface antigens, or transcription factors) have been 
found to characterize distinct stages of oligodendrocyte differentiation. These 
markers have specific functions when it comes to the gene regulatory 
mechanisms and protein interactions that allow for the oligodendrocyte to 
develop normally. There are several types of signals that regulate 
oligodendrocyte development. While there has been considerable debate about 
whether in vivo and in vitro models yield the same findings concerning the 
oligodendrocyte lineage, much of the signaling properties that have been 
characterized in vitro hold true to what naturally occurs in animal systems 
(Lazzarini, 2004, Nishiyama et al., 2009). These specific cell markers along with 
a change in the cellular morphology allow for proper identification and study of 
oligodendrocyte development (Pfeiffer et al., 1993, Baumann and Pham-Dinh, 
2001, Bradl and Lassmann, 2010). 
 Markers of oligodendrocyte development consist of lipids and proteins 
expressed by one or more stages of the oligodendrocyte lineage. Olig2 is a 
transcription factor that has been implicated in regulating the specification of 
oligodendrocyte progenitor cells and remains expressed throughout the lineage 
in rodents (Liu et al., 2007). Sox10 is another transcription factor expressed and 
regulates development of oligodendrocyte progenitor cells once they become 
specified and remains expressed throughout the oligodendrocyte lineage (Liu et 
al., 2007).  In the rodent model system, one of the early cell surface lipids for 
premature oligodendrocytes is identified by the antibody A2B5.  This antibody 
 
 
 
 
 
13 
recognizes several gangliosides on the cell surface (Raff et al., 1983, Raff et al., 
1984, Pfeiffer et al., 1993, Baumann and Pham-Dinh, 2001, Baracskay et al., 
2007, Bradl and Lassmann, 2010). This antibody characterizes an early bipolar 
or unipolar morphology of an oligodendrocyte progenitor cell and the lipids it 
recognizes are downregulated as the cell differentiates into a more mature 
oligodendrocyte (Raff et al., 1983, Raff et al., 1984, Pfeiffer et al., 1993, 
Baumann and Pham-Dinh, 2001, Baracskay et al., 2007, Bradl and Lassmann, 
2010) (Figure 1.2). These A2B5+ oligodendrocyte progenitor cells are highly 
migratory and proliferative in the presence of platelet derived growth factor 
(PDGF) (Richardson et al., 1988, Gard and Pfeiffer, 1993, Pringle and 
Richardson, 1993). In the in vivo system, PDGF is thought to be secreted by 
neuronal cell bodies and astrocytes (Richardson et al., 1988, Fruttiger et al., 
2000, Rosenberg et al., 2007) (Figure 1.3).  PDGF increases the proliferation and 
survival of oligodendrocyte progenitor cells (Hart et al., 1989a, Hart et al., 
1989b). Since PDGF signals to these oligodendrocyte progenitor cells, the 
receptor that they express for PDGF is another marker often used to identify 
them (Richardson et al., 1988, Gard and Pfeiffer, 1993, Pringle and Richardson, 
1993). This receptor is the platelet derived growth factor receptor alpha 
(PDGFRα). Basic fibroblast growth factor (bFGF) is a growth factor and mitogen 
to which early oligodendrocytes respond (Fok-Seang and Miller, 1994).  The 
combination of both PDGF and bFGF promotes cell proliferation and inhibits 
differentiation (Gard and Pfeiffer, 1993, Pfeiffer et al., 1993). 
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 As oligodendrocyte development progresses, mitogenic factors wane and 
oligodendrocytes are then introduced to the differentiating factor thyroid hormone 
(TH). TH and a lack of mitogenic factors are necessary for oligodendrocyte 
progenitor cell maturation (Barres et al., 1994, Franco et al., 2008) (Figure 1.3).  
As the oligodendrocyte progenitor cells change biochemically, changes in 
morphology are occurring simultaneously. Oligodendrocytes become multipolar 
and reactive with the mouse monoclonal antibody O4, which binds to an 
uncharacterized surface antigen (POA) and sulfatide (Bansal et al., 1989, Bansal 
et al., 1992)(Figure 1.2). This seems to be the last point where these O4 
expressing cells have proliferative capabilities.  From this point on, their 
postmigratory stage of life is slowing and will soon end (Warrington and Pfeiffer, 
1992). 
CNP (2',3'-cyclic nucleotide 3'-phosphodiesterase) is a marker for more 
mature, so-called premyelinating oligodendrocytes (Trapp et al., 1988) (Figure 
1.2). CNP is a protein that catalyzes 2’,3’-cyclic nucleotides to make 
2’nucleotides. In addition to its presence in premyelinating oligodendrocytes, it is 
also seen in uncompacted myelin in the paranodal loops (Wells and Sprinkle, 
1981, Nave and Trapp, 2008). The biological role of CNP in vivo is not well 
understood to date. However, when CNP is overexpressed in mice, premature 
and abnormal myelination is observed and when overexpressed in vitro, it 
promotes process outgrowth (Lee et al., 2005, Nave and Trapp, 2008). The roles 
in CNP regulating the cytoskeleton have been described in the “Oligodendrocyte 
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differentiation – changes in actin cytoskeletal organization” section of the 
introduction. 
Cells of the oligodendrocyte lineage that are O4 positive and CNP positive 
are post mitotic and terminally differentiated cells that begin to express myelin 
markers such as myelin basic protein (MBP), proteolipid protein (PLP), myelin 
associated glycoprotein (MAG), myelin-oligodendrocyte glycoprotein (MOG), and 
the galactocerebrosides (GalC) that are recognized by the O1 antibody (Figure 
1.2).  At this stage, the beginnings of membranous sheets develop in culture and 
these cells are classified as mature oligodendrocytes (Bansal et al., 1989). The 
myelinating oligodendrocyte will remodel its process network and extensively 
produce myelin membranes to wrap axonal segments (Helmut Kettenmann, 
2005, Bauer et al., 2009).  
MBP is one of the major myelin protein components in the CNS (Baumann 
and Pham-Dinh, 2001, Helmut Kettenmann, 2005). One of MBP’s functions is the 
compaction and binding of opposing cytoplasmic myelin membranes (Readhead 
et al., 1990). MBP’s role in compaction is made evident in the shiverer mutant 
mouse line. In this mouse line, the Mbp gene is mostly deleted and the protein is 
absent resulting in hypomyelination and the formation of uncompacted myelin in 
the CNS (Readhead and Hood, 1990, Readhead et al., 1990, Shine et al., 1990). 
MBP is expressed in multiple isoforms in the rodent and other mammalian 
systems. In the mouse, MBP contains 7 exons which through alternative splicing 
of exons 2, 5 and 6 account for the four major “classic “ MBP variants 
(Campagnoni, 1988, Campagnoni and Macklin, 1988, Baumann and Pham-Dinh, 
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2001, Helmut Kettenmann, 2005). The molecular weight of each one of the 4 
classic MBP’s are: 21.5kDa, 18.5kDa, 17kDa, and 14kDa (Helmut Kettenmann, 
2005). The splicing of these different transcripts is developmentally regulated. 
This can be seen in the larger 17 and 21.5kDa isoforms that contain exon2. 
Exon2 containing MBP is seen early on during oligodendrocyte differentiation, 
and interestingly, it is also seen in chronic MS samples where presumed limited 
and insufficient remyelination is occurring (Capello et al., 1997, Nagasato et al., 
1997). The non-exon 2 containing isoforms are considered specific for the 
myelinating stages of the lineage (Campagnoni, 1988, Campagnoni and Skoff, 
2001).  
Proteolipid protein (PLP) is another major myelin protein component in the 
CNS. This highly conserved protein is a cell-surface protein that spans the 
membrane four times, forming two extracellular loops, which are thought to 
mediate adhesion between the outer (extra cellular side) membranes of the 
myelin sheath (Popot et al., 1991, Baumann and Pham-Dinh, 2001). PLP has a 
splice variant with the name DM20 (Campagnoni, 1988, Timsit et al., 1995, Nave 
and Trapp, 2008).  Plp1/Dm20 is a 7 exon encoded gene, where use of an 
internal splice donor site within exon 3 results in a 35 amino acid deletion 
generating the splice variant DM20 (Helmut Kettenmann, 2005). The expression 
of each one of these splice variants is developmentally regulated, where DM20 is 
the earlier expressed isoform and PLP is expressed later as the oligodendrocyte 
matures (Timsit et al., 1995).  
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Functionally, the significance of PLP has been demonstrated by mouse 
mutant and knockout studies.  The PLP mutant mouse jimpy, which has a mutant 
form of the protein, has a reduced number of oligodendrocytes and thin myelin 
resulting in premature death (Knapp et al., 1986, Duncan et al., 1989). However, 
in Plp1 knockout mice, there is no oligodendrocyte loss or loss of myelin. Axonal 
swellings and axonal degeneration were noticed in these animals; therefore, the 
phenotypic response seen in the jimpy mice has been suggested to be a result of 
protein misfolding in the mutant PLP (Griffiths et al., 1998). 
 
The oligodendrocyte cytoskeleton  
From specification to myelination, oligodendrocytes not only progress 
through changes in gene expression but they also undergo extensive changes in 
morphology. Oligodendrocyte morphological development can be broken down 
into three steps. The first step is cell spreading and formation/extension of a 
complex process network. The second step is the establishment of axonal 
contact and the extension/spreading of the myelin sheath. Compaction and 
maintenance of the myelin sheath is the final stage (Bauer et al., 2009).  All of 
the three steps mentioned above require large-scale morphological changes in 
the oligodendrocyte that will eventually make the myelin sheath. These large-
scale changes are mediated to a large extent by changes in the cellular 
cytoskeleton (Bauer et al., 2009).  
The oligodendrocyte cytoskeleton is composed of microtubules and 
microfilaments. These cytoskeletal components and many of their regulatory 
 
 
 
 
 
18 
elements are also found in other types of cells. This is in contrast to intermediate 
filaments, which are present in the non-oligodendroglia CNS cell types 
(astrocytes and neurons) but absent in cells of the oligodendrocyte lineage 
(Bauer et al., 2009). Microfilaments and microtubules are both part of the 
cytoskeleton but their roles differ somewhat when it comes to function. Process 
outgrowth is primarily mediated by microfilaments because of their location and 
their ability to directly connect via actin binding proteins to the plasma membrane 
(Bauer et al., 2009). Microtubules, on the other hand, are primarily thought to 
mediate process stability and localize to the cellular process once the 
microfilament network has moved the process forward (Bacon et al., 2007, Chan 
et al., 2009, Pollard and Cooper, 2009).  Furthermore, both microtubules and 
microfilaments are polarized polymers and both can be associated with motor 
proteins such as kinesins, dyneins, and myosins for the transport of cellular 
organelles, vesicles, proteins, and mRNAs (Ross et al., 2008). The polarity of 
these cytoskeletal proteins is based on the direction and site of addition of 
subunits to the growing polymer. The fast growing end (or plus end) of these 
polymers is termed thusly because it is the site of addition of individual subunits 
while the opposite end (the minus end) is unstable and usually the site of 
depolymerization (Bauer et al., 2009, Pollard and Cooper, 2009).  
 Microtubules are comprised of alpha and beta-tubulin heterodimers. 
These heterodimers form a classic hollow cylindrical tube. In the cellular 
processes of oligodendrocytes, microtubules are arranged parallel to the 
orientation of the process (Lunn et al., 1997, Song et al., 2001, Bauer et al., 
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2009). In the cell body of the oligodendrocyte, however, the microtubule network 
is arranged in a mesh-like pattern (Lunn et al., 1997). It has been shown that 
oligodendrocytes express a unique form of beta tubulin (βIV-tubulin) that is 
apparently not expressed by any other CNS-derived cell (Terada et al., 2005). 
The function of this unique form of tubulin is still under investigation. Microtubules 
can go through post-translational modifications including acetylation. Acetylated 
α-tubulin seems to be associated with stable processes in more mature 
oligodendrocytes since it appears to be present in primary processes but not at 
the most distal tips of the process (Lunn et al., 1997, Song et al., 2001). 
The other cytoskeletal component that oligodendrocytes possess is actin. 
Actin is found in oligodendrocytes in two distinct forms: globular monomer (G-
actin) and filamentous (F-actin) (Song et al., 2001, Le Clainche and Carlier, 
2008, Pollard and Cooper, 2009). F-actin is formed by the polymerization of G-
actin subunits.  Spontaneous nucleation of G-actin is not likely because of the 
stability of actin and the high threshold of nucleation that actin possesses (Bauer 
et al., 2009, Pollard and Cooper, 2009). Actin utilizes specific actin binding and 
regulatory proteins that act as catalysts for actin nucleation. Two examples for 
such proteins are the actin related protein 2/3 (Arp2/3) complex and the formin 
family of proteins (Bacon et al., 2007, Bauer et al., 2009, Chan et al., 2009, 
Pollard and Cooper, 2009).  
 
Oligodendrocyte differentiation – changes in actin cytoskeletal 
organization  
 
 
 
 
 
20 
For the purposes of this dissertation, understanding the cytoskeletal 
changes that occur during oligodendrocyte differentiation is critical for a better 
understanding of the signaling pathways that regulate oligodendrocyte 
differentiation and that could be targeted to stimulate endogenous repair of the 
myelin sheath in MS.  Process extension is the initial step in oligodendrocytes 
developing a complex process network and subsequently the myelin sheath. 
Once terminal differentiation has occurred, a complex process network is 
established by rearranging and reorganizing the cellular cytoskeleton (Bauer et 
al., 2009). This process requires well coordinated polymerization and de-
polymerization that regulates the changes that are occurring (Bradke and Dotti, 
1999, Mallavarapu and Mitchison, 1999, Pollard and Cooper, 2009, Koskinen et 
al., 2012). The term named for this addition of subunits (polymerization) to the 
positive end of the microfilament and the removal of subunits (depolymerization) 
from the minus end of the subunit is called treadmilling. In general, process 
outgrowth and membrane sheet formation are mediated by filopodia and 
lamellipodia production; the generation of which is caused by stimulation of actin 
polymerization as well as actin filament branching and bundling (Song et al., 
2001, Bacon et al., 2007, Pollard and Cooper, 2009). Filopodia are formed in the 
presence of parallel F-actin finger-like bundles that are the driving force of 
process extension. Lamellipodia are the lagging structures that fall into formation 
after filopodia have somewhat extended. It is generally understood that filopodia 
are formed first and then due to branching, the lamellipodia push out the leading 
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edge of the oligodendrocyte process (Song et al., 2001, Bacon et al., 2007, 
Pollard and Cooper, 2009).  
 The actin dynamics that control filopodia and lamellipodia formation and 
movement are regulated by actin binding proteins such as the Arp 2/3 complex 
and neural-Wiskott Aldrich Syndrome Protein (N-WASP) (Bacon et al., 2007, 
Delatour et al., 2008). Arp2/3 is a complex that binds to the sides of existing 
("mother") filaments and initiates growth of a new ("daughter") filament at a 
distinctive angle from the mother filament and initiates branching of F-actin 
filaments (Pollard, 2007, Delatour et al., 2008). N-WASP has been shown to aid 
in actin filament branching by interacting with Arp2/3 (Bacon et al., 2007). 
Importantly, N-WASP has been shown to be required for lamellipodia formation 
in maturing oligodendrocytes (Bacon et al., 2007).  Rho GTPases signal to many 
of the actin-associated proteins and promote actin polymerization or 
depolymerization. Rho GTPases are major regulators of the actin cytoskeleton 
and mediate process elongation and branching as well as inhibition of process 
formation (Bauer et al., 2009). The three most common and best studied 
members of the Rho GTPase family are CDC42, Rac1, and RhoA.  Process 
retraction is often found mediated by the activation of RhoA.  RhoA in turn 
activates ROCK, which signals to the actin cytoskeleton to initiate process 
retraction (Wolf et al., 2001). In contrast to RhoA, activation of CDC42 and Rac1 
results in process outgrowth by stimulating actin polymerization and branching 
(Colognato et al., 2002, Bacon et al., 2007, Sloane and Vartanian, 2007). 
Interestingly, knockout of CDC42 or Rac1 in mice does not result in deficient 
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myelin formation. This could be due to the redundancy of the two actin 
polymerizing proteins that can compensate for each other (Thurnherr et al., 
2006).  
In addition to actin polymerization, the depolymerization or (breaking 
down) of the actin cytoskeleton by certain factors is equally important in the 
formation and extension of new and current oligodendrocyte processes. It is 
critical that the periods of actin destabilization be followed up with periods of actin 
stabilization to achieve a proper balance of actin dynamics (Ballestrem et al., 
1998, Bradke and Dotti, 1999). Oligodendrocytes express the actin 
depolymerizing factor cofilin, which appears to be localized to the 
oligodendrocyte “growth cone” (Fox et al., 2006a). Other than localization, much 
of the function of cofilin has not been specifically described in oligodendrocytes 
as it has been in other cell types. However, based on the localization and 
conservation of the protein, it is assumed that cofilin functions as an actin 
depolymerizer similar to its role in Schwann cells and other cell types (Sparrow et 
al., 2012). This depolymerization of the actin cytoskeleton by cofilin allows the 
redistribution of actin filaments by breaking down longer filaments into shorter 
filaments and monomeric subunits (Lappalainen and Drubin, 1997, Sparrow et 
al., 2012).   
In addition to actin binding proteins and Rho GTPases, there are several 
other proteins that are linked to process extension in more mature 
oligodendrocytes. Fyn, a member of the Src family kinases (SFK), promotes 
process extension and morphological differentiation by inactivating RhoA (Wolf et 
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al., 2001, Liang et al., 2004). This inactivation of RhoA is developmentally 
regulated and upon inactivation by Fyn, there is an increase in process extension 
(Wolf et al., 2001, Liang et al., 2004). Dominant negative constructs in vitro or 
knockout and mutants in vivo have shown that Fyn is necessary for proper 
myelination of the CNS. When Fyn is downregulated in vitro or knocked out in 
vivo, process outgrowth is inhibited and a hypomyelination phenotype is 
observed respectively (Wolf et al., 2001, Klein et al., 2002, Liang et al., 2004).  
Fyn has many downstream effects on process extension. One of these 
down stream effects is the inhibition of Myosin II, which seems to increase 
process extension in oligodendrocytes. Actin-associated motor protein non-
muscle myosin II (NMII) is regulated by phosphorylation of a specific regulatory 
chain and is a key regulator of actinomyosin assembly. More specifically, activity 
of NMII in oligodendrocytes is controlled by Fyn kinase via downregulation of 
RhoA-ROCK-NMII phosphorylation (NMII inhibition) (Conti and Adelstein, 2008, 
Wang et al., 2008, Wang et al., 2012).  When myosin II is inhibited in culture, 
there is an increase in actin polymerization, branching, and the amount of 
myelinated segments formed in a co-culture system (Conti and Adelstein, 2008, 
Wang et al., 2012).  
 Kelch-related acting binding protein Mayven is also linked to process 
extension in differentiating oligodendrocytes (Jiang et al., 2005). Mayven is 
expressed and upregulated during oligodendrocyte differentiation where 
oligodendrocytes form a more complex process network. Mayven promotes 
process extension by binding actin to facilitate cytoskeletal rearrangement (Jiang 
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et al., 2005). Mayven protein binding domains suggest that Fyn and Mayven may 
interact and play a role in the dynamics of cytoskeletal rearrangement leading to 
process extension (Jiang et al., 2005).  
Major myelin proteins have also been shown to affect the actin 
cytoskeleton and process extension. For example, MBP has been shown to act 
as a scaffolding protein that links the lipid bilayer to bind actin, induces F-actin 
polymerization, and bundles actin in a phosphorylation dependent manner 
(Boggs, 2006, Boggs et al., 2006, Boggs et al., 2012).  MBP is not 
phosphorylated when located within the sheets of myelin; therefore it can not 
perform as a scaffolding protein (Boggs, 2006, Boggs et al., 2006, Boggs et al., 
2012).  When MBP is phosphorylated, it is localized in the cell body. This 
phosphorylated state of MBP prevents interaction with actin in the 
oligodendrocyte cell body (Boggs, 2006, Boggs et al., 2006, Boggs et al., 2012).    
CNP is another myelin protein that affects the cytoskeleton of 
oligodendrocytes. Studies show that when CNP is upregulated before and during 
myelination, it can bind to both microtubules and microfilaments. More 
specifically, CNP acts in the processes of cells and aids the connections of the 
actin cytoskeleton to the membrane. Studies have suggested that CNP is 
important in filopodia formation in oligodendrocytes (De Angelis and Braun, 
1996a, b).  
All of the actions described above are internally derived in the cell. 
However, extracellular matrix (ECM) components and signaling molecules signal 
to internal proteins governing process formation and extension. The ECM 
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components laminin, fibronectin, and collagen all interact with membrane 
proteins such as integrins. These integrins are heterodimers made of an α and a 
β-chain. Oligodendrocytes express αvβ1, αvβ3, αvβ5, α6β1, and αvβ8 
(Colognato et al., 2002, Benninger et al., 2006, Colognato and Tzvetanova, 
2011). Most of these integrins (especially the αv integrins) seem to be 
developmentally regulated and expressed at different stages of oligodendrocyte 
development (Colognato and Tzvetanova, 2011).  It should be noted that α6β1 
integrin seems to play a key role in the axo-glial interaction that controls CNS 
myelin wrapping (Lee et al., 2006). 
 Simply put, oligodendrocyte process extension is assisted by a 
conglomeration of different actin binding proteins and signaling molecules that 
mainly function in two roles by either allowing actin to polymerize or to 
depolymerize and rearrange the actin cytoskeleton. Both of these functions can 
happen simultaneously and when combined, allow for constant fluidity in the 
actin cytoskeleton and proper process elongation. There has been a good 
amount of research based on the characterization of the molecular players that 
govern polymerization and depolymerization. However, little is known about the 
molecular players that regulate stabilization of the actin cytoskeleton. The data 
highlighted in this dissertation demonstrates the importance of the actin 
binding/stabilizing protein Calcium/calmodulin-dependent protein kinase II beta 
(CaMKIIβ) described below.  
 
Calcium/calmodulin-dependent protein kinase II (CaMKII)  
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 Calcium/calmodulin-dependent protein kinase II (CaMKII) has been mainly 
described as a fine-tuned calcium sensor and fundamental kinase for neuronal 
activity in the development of memory and synaptic plasticity in the CNS 
(Hudmon and Schulman, 2002b, a, Griffith, 2004). Much of the research on 
CaMKII’s role in neurons has focused on understanding the mechanism of 
synaptic plasticity and increases in long-term potentiation (LTP), which is critical 
in learning and memory (Hudmon and Schulman, 2002b, a, Griffith, 2004). 
 Research highlighting CaMKII’s relationship with oligodendrocytes is rare.  
Currently, there are only a couple of research articles in the literature.  In one of 
the articles, CaMKII’s expression in oligodendrocytes was only mentioned as part 
of their supplemental microarray data (Dugas et al., 2006). Another mention of 
CaMKII being involved in oligodendrocytes comes from a publication in which the 
myelin proteome was characterized (Jahn et al., 2009). Since CaMKII has hardly 
been described in oligodendrocytes, little is known about CaMKII’s role and 
function in these cells. The lack of research into the function and expression of 
CaMKII in oligodendrocytes is likely not due to its lack of importance compared to 
neurons; rather, it is probably due to the overwhelming amount of researchers 
characterizing synaptic plasticity and learning and memory in neurons.  
Additionally, expression levels of CaMKII are much higher in neurons and may 
have been overlooked in oligodendrocytes. Given the similarities in certain 
aspects of morphological maturation between oligodendrocytes and neurons, it is 
plausible to apply some of the findings in CaMKII neuronal research to 
oligodendrocyte development (Fox et al., 2006a).  
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 Calcium/calmodulin-dependent protein kinase II (CaMKII) is a serine/ 
threonine kinase (Hudmon and Schulman, 2002b, a, Griffith, 2004) that 
phosphorylates substrates at a serine or threonine site (Hudmon and Schulman, 
2002b, a, Griffith, 2004). CaMKII encodes four different genes in the mammalian 
system (Hudmon and Schulman, 2002b, a, Griffith, 2004) and seven different 
genes in teleosts (Rothschild et al., 2007, Rothschild et al., 2009). In the 
mammalian system, these genes are given the names Camk2a, Camk2b, 
Camk2g, and Camk2d. Multiple splice variants exist with each of these genes 
(Hudmon and Schulman, 2002b, a, Griffith, 2004). 
 
Basic structure and organization of CaMKII 
 CaMKII contains several functional domains within its protein structure. 
The catalytic domain which is located at the N-terminal end of the protein is 
where ATP and substrate binding sites are located (Hudmon and Schulman, 
2002b, a, Griffith, 2004) (Figure 1.4). The regulatory region is upstream of the 
catalytic domain and consists of two domains (Figure 1.4). The two domains in 
this regulatory region are an autoinhibitory domain and a Ca2+/ CaM binding 
domain (Hudmon and Schulman, 2002b, a, Griffith, 2004) (Figure 1.4).  These 
two domains regulate the activation of CaMKII. (Hudmon and Schulman, 2002b, 
a). The association domain is located C-terminal to the Ca2+/ CaM binding 
domain (Hudmon and Schulman, 2002b, a) (Figure 1.4). In between the 
association domain and the regulatory domain is a variable domain or “linker 
domain” (Griffith, 2004, Kristensen et al., 2011). This domain contains isozyme-
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specific regions and multiple splice variants (Hudmon and Schulman, 2002b, a, 
Griffith, 2004). The association domain allows CaMKII monomers to join 
together, forming a large functional 12-subunit holoenzyme (Schulman and 
Greengard, 1978a, b, Hudmon and Schulman, 2002b, a, Griffith, 2004) (Figure 
1.5). They can form homo and hetero-oligomers containing more than one 
Camk2 gene. Hetero-oligomerization provides inter-subunit phosphorylation 
when CaMKII is being activated (Griffith, 2004, Lantsman and Tombes, 2005). 
 
Activation of CaMKII’s catalytic activity 
After the binding of calcium (Ca2+) to calmodulin (CaM), Ca2+/ CaM binds 
with high affinity to the Ca2+/CaM binding site within the regulatory domain of 
CaMKII (Hudmon and Schulman, 2002b, a, Griffith, 2004) (Figure 1.5).  After the 
binding of Ca2+/ CaM to its appropriate binding site, autophosphorylation occurs. 
The autoinhibitory domain releases the catalytic domain, allowing access to 
phosphorylation sites critical for inter-subunit phosphorylation of the Thr286 site 
(for CaMKIIα) (Hudmon and Schulman, 2002b, a, Griffith, 2004) (Figure 1.5). 
Once the subunits are phosphorylated, the kinase remains at 100 percent of its 
activity even after intracellular calcium levels fall (Hudmon and Schulman, 2002b, 
a, Griffith, 2004) (Figure 1.5).  Ca2+/ CaM is tightly bound to the binding site, 
creating a state of activity known as “active-CaM trapped” (Hudmon and 
Schulman, 2002b, a, Griffith, 2004) (Figure 1.5). Over time, Ca2+/ CaM 
dissociates from the kinase and CaMKII will remain active at a lower state. This 
state is known as the active-Ca2+ independent state (Hudmon and Schulman, 
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2002b, a, Griffith, 2004) (Figure 1.5). After Ca2+/ CaM dissociates from CaMKII, 
two other threonine sites are exposed and can be autophosphorylated. Once 
these two other threonine (Thr306 and Thr307) sites (for CaMKIIα) have been 
phosphorylated, the phosphates block the Ca2+/ CaM binding site and do not 
allow further association with Ca2+/ CaM (Hudmon and Schulman, 2002b, a, 
Griffith, 2004) (Figure 1.5). This state, called “active capped,” possesses only 20 
to 80 percent of CaMKII’s full capacity of activity (Hudmon and Schulman, 2002b, 
a, Griffith, 2004) (Figure 1.5). Over time, phosphatases act and return the 
partially active CaMKII to its inactive state (Griffith, 2004) (Figure 1.5). 
 
CaMKII as an actin binding and actin cytoskeleton regulatory protein 
It has been recently shown that CaMKII can play a role in the regulation of 
the actin cytoskeleton (Shen et al., 1998, Fink et al., 2003, O'Leary et al., 2006, 
Okamoto et al., 2007, Lin and Redmond, 2008, 2009, Sanabria et al., 2009).   
The CaMKII isoform that has been best described for the binding to F-actin is the 
β isozyme (Shen et al., 1998). Further supporting the relationship between actin 
and CaMKII, studies using RNA interference targeted to CaMKIIβ resulted in a 
significant reduction of actin synaptic volume (Okamoto et al., 2007, Lin and 
Redmond, 2008, 2009, Okamoto et al., 2009). It has been shown that 
oligomerization of CaMKIIβ is needed for actin binding but catalytic activity is not 
essential for actin binding (Okamoto et al., 2007, Lin and Redmond, 2008). An 
actin binding domain that is N-terminal within the variable domain of CaMKIIβ is 
responsible for F-actin binding (O'Leary et al., 2006, Okamoto et al., 2007). 
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The structure and the composition of the variable domain play a key role 
in the protein’s regulation and binding abilities to actin. Expression of Camk2b in 
the adult brain is prevalent with the splice variants of exons 1,2,3,4 and 5 in the 
variable region. These results further support the evidence that strict control over 
an important actin binding element is regulated with fine precision. Exon 1 in the 
variable domain seems to be the actin binding region that is unique to Camk2b 
(O'Leary et al., 2006). The first, third, and/or fourth exon in the variable region 
seem to control the targeting to the F-actin cytoskeleton.  Deletion of exon 1 in 
the variable region inhibits actin bundling and colocalization with bundled actin, 
demonstrating that the first exon in the variable region is critical for binding and 
bundling of actin (O'Leary et al., 2006).  
The function of CaMKIIβ is more complex than only its use as a 
multifunctional kinase. CaMKIIβ is responsible for the reorganization and 
stabilization of the actin cytoskeleton (Sanabria et al., 2009). While CaMKIIβ 
seems to possess a unique actin binding site, other CaMKII isoforms have been 
recently reported to also bind to actin via a location C-terminal to the variable 
domain (Hoffman et al., 2013). 
CaMKIIβ has been shown to play an important role in the regulation of 
actin dynamics within the dendritic spine (Okamoto et al., 2007, Okamoto et al., 
2009, Sanabria et al., 2009). The model that has been proposed by Okamoto et 
al. (2009) uses CaMKIIβ as a “gating” mechanism that will maintain spine 
structure at Ca2+ resting levels. When Ca2+ levels increase, modification of the 
actin cytoskeleton is observed.  CAMKIIβ then preserves the new modification for 
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periods of time (Okamoto et al., 2009).  This proposed model starts off with 
CaMKIIβ bundling actin in a resting basal state in the dendritic spine. Once Ca2+ 
enters the cell and activates CaMKIIβ, it disassociates from actin and allows for 
F-actin unbundling. Actin polymerization, F-actin rearrangement, and spine 
enlargement soon follow after dissociation of CaMKIIβ from f-actin bundles. 
Lastly, CaMKIIβ will once again accumulate in the dendritic spine and bundle   
the newly rearranged f-actin bundles, allowing for cytoskeletal stabilization 
(Okamoto et al., 2009).  
The model of CaMKIIβ described by Okamoto et al. (2009) is supported by 
many experiments that show the relevance of CaMKIIβ location and its 
association with the actin cytoskeleton.  By overexpressing Camk2b, researchers 
have observed an accumulation of the protein in spines.  When CaMKII is 
inhibited (CaMKII inhibitor KN-93), researchers also observed alternations and 
spine remodeling.  The overexpressed accumulation of CaMKIIβ in these 
dendritic spines demonstrates the fact that the protein is bundling actin and 
stabilizing the spine structure in an activity-dependent manner (Shi and Ethell, 
2006, Okamoto et al., 2007, Okamoto et al., 2009).  
 The actin network is responsible for the outgrowth of dendrites.  When 
CaMKIIβ is knocked down, it impairs outgrowth of these dendrites (Fink et al., 
2003). In addition to binding and bundling F-actin, CaMKIIβ binds to monomeric 
actin (G-actin) and inhibits actin polymerization that is diminished by the binding 
of Ca2+/ CaM (Sanabria et al., 2009). This binding of G-actin enhances the 
structural rigidity of F-actin (Sanabria et al., 2009). Furthermore, CaMKIIβ has 
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been shown to control the rate and extension of actin polymerization through 
binding and sequestration of G-actin (Sanabria et al., 2009, Hoffman et al., 
2013). 
CaMKIIβ activation by autophosphorylation can facilitate actin unbinding 
(O'Leary et al., 2006, Okamoto et al., 2007, Okamoto et al., 2009, Sanabria et al., 
2009). When using different mutant constructs, strong correlations with 
colocalization are seen in the A303R (calmodulin binding mutant) mutant and the 
K43R (autophosphorylation mutant) mutant. This demonstrates that CaMKIIβ 
binds to actin in a catalytic independent/dependent manner. Once the 
phosphorylation of the main autophosphorylation site is activated, CaMKIIβ 
appears unbound to actin. This result is shown when using the T287D 
(constitutively active mutant) mutant that did not show colocalization with actin in 
Cos-7 cells when transfected (O'Leary et al., 2006). CaMKIIβ binding to F-actin 
did not increase phosphorylation of a substrate peptide, indicating that the 
activation state of the kinase was not changed (Fink et al., 2003). 
Although the CaMKIIβ information presented in this section is based on 
neuronal research, the findings can be applied to oligodendrocytes due to the 
commonalities in the actin cytoskeleton. In oligodendrocytes as well as neurons, 
the actin cytoskeleton plays a critical role in the formation, extension, and 
remodeling of processes that extend from the cell body.  CaMKII’s involvement in 
oligodendrocyte development is potentially imperative, as oligodendrocytes are 
dependent on creating these complex processes and maintaining a regulation of 
the cytoskeleton similar to the model proposed in neurons. 
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Figure 1.1: Oligodendrocyte origination points and migratory patterns in brain 
and spinal cord. A: Red represents the first wave of development and migration 
in the rodent ventral spinal cord. Green represents the origination and migration 
of the second wave of development in more dorsally located positions of the 
spinal cord. B: Rodent brain displaying sagittal section (upper) showing the site 
of origination for oligodendrocytes and (orange) their rostral caudal radial 
migration to populate the cortex (green arrows). The rostral migratory stream is 
the specialized rout that allows cells to migrate to the olfactory bulb from the SVZ 
(red). Coronal sections of the rodent brain (lower) showing oligodendrocyte 
origination from the SVZ (orange) and their dorsolateral radial migration pattern 
from the SVZ into the cortex (green arrows).  Adapted from (Cayre et al., 2009; 
Richardson et al., 2006). 
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Figure 1.2: Oligodendrocyte lineage and some specific markers that are 
expressed at different developmental stages.  Adapted from (Baracskay et al., 
2007; de Castro and Bribian, 2005; Fox et al., 2004; Pfeiffer, et al.,1993). 
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Figure 1.3: Signaling network of oligodendrocyte development. Green arrows 
indicate stimulation. Red bars indicate repression or inhibition. Blue arrows 
represent developmental time between stages of oligodendrocyte development. 
Adapted from (Nicolay et al., 2007). 
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Figure 1.4: The structure and functional domains of CaMKII. Phosphorylation 
sites are representative for CaMKIIα. The phosphorylation sites depicted are 
conserved between CaMKII isozymes (Lisman et al., 2002). 
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Figure 1.5: Activation of CaMKII. A six subunit holoenzyme rather than a 12 
subunit holoenzyme is shown for simplicity. Phosphorylation sites are 
representative for CaMKIIα (Griffith, 2004b). 
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CHAPTER 2 
 
CaMKIIβ Regulates Oligodendrocyte Maturation and CNS Myelination 
(This chapter was accepted as a paper in the Journal of Neuroscience in May of 
2013. The work reported for this manuscript is based primarily on my own efforts. 
Assistance was provided by Dr. Jeffrey Dupree (electron microscope imaging 
Figure 2.4)  
 
 
Introduction 
During development, oligodendrocytes, the myelinating cells of the central 
nervous system (CNS), undergo a lineage progression during which bipolar 
progenitors give rise to cells with an extended process network that then 
transition into mature oligodendrocytes generating the myelin sheath (Pfeiffer et 
al., 1993, Baumann and Pham-Dinh, 2001). The morphological aspects of this 
progression are to a large extent regulated by changes in the cellular 
cytoskeleton (Bauer et al., 2009). However, the exact mechanisms by which the 
cellular cytoskeleton regulates oligodendrocyte maturation and CNS myelination 
are currently only poorly understood.  
One of the molecular players that emerges as an important regulator of the 
actin cytoskeleton is calcium/calmodulin-dependent kinase type IIβ (CaMKIIβ). 
CaMKIIβ belongs to a family of highly conserved serine/threonine kinases, which 
in mammals is encoded by four different genes (Camk2a, Camk2b, Camk2g, 
Camk2d) giving rise to four isozymes (CaMKIIα, CaMKIIβ, CaMKIIγ, CaMKIIδ) 
(Tombes et al., 2003). Structure-functionally, CaMKII monomers are composed 
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of four domains, a kinase catalytic, an autoinhibitory (regulatory), an association 
(oligomerization) and a central variable domain that is subject to alternative 
splicing and located distal to the autoinhibitory domain (Hudmon and Schulman, 
2002b). Interestingly, CaMKIIβ has been characterized to also possess a 
distinctive actin binding domain (Okamoto et al., 2009), which has been 
implicated in mediating actin filament stabilization/bundling (Shen et al., 1998, 
Fink et al., 2003, O'Leary et al., 2006, Okamoto et al., 2007, Lin and Redmond, 
2008). While primarily characterized in neurons, CaMKII genes including 
CaMKIIβ appear to also be expressed by cells of the oligodendrocyte lineage 
(Cahoy et al., 2008). Thus, we examined here the role of CaMKII and in 
particular CaMKIIβ in regulating oligodendrocyte maturation and myelination.  
 
Materials and Methods 
Animals. Sprague-Dawley female rats with early postnatal litters were obtained 
from Harlan Laboratories, Inc. (Indianapolis, IN).  Camk2b-/- and Camk2bA303R 
mice (both in the F2 129P2-C57BL/6 background; van Woerden et al., 2009; 
Borgesius et al., 2011) were generated and bred at Erasmus University Medical 
Center. Animal studies were approved by the Institutional Animal Care and Use 
Committee at Virginia Commonwealth University or a Dutch Ethical Committee 
for animal experiments.  
Primary oligodendrocyte cultures. Primary oligodendrocytes were isolated 
from P3 rat brains by A2B5 immunopanning (Barres et al., 1992) and then 
cultured in differentiation medium for at least 48 hours (Lafrenaye and Fuss, 
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2011). Under these conditions, the majority of cells represented post-migratory, 
premyelinating oligodendrocytes as they expressed the O4 antigen (Sommer and 
Schachner, 1982, Warrington et al., 1993) (data not shown). 
For CaMKII inhibition experiments, cells were cultured for 44 to 48 hours 
followed by incubation with 1) KN-93 or its inactive analog KN-92 (EMD Millipore, 
Billerica, MA), 2) myristoylated autocamtide-2 related inhibitory (Myr-AIP) or 
myristoylated control (scrambled AIP sequence) peptide (Enzo Life Sciences, 
Inc., Farmingdale, NY) or 3) KN93 or KN92 in combination with jasplakinolide 
(Enzo Life Sciences, Inc., Farmingdale, NY).  
For siRNA-mediated gene silencing, cells were cultured for 20 to 24 hours 
and then transfected with siGLO Green transfection indicator along with either an 
siRNA SMARTpool directed against rat Camk2a, b, g or d or a control non-
targeting siRNA SMARTpool (all from Thermo Fisher Scientific, Inc., Waltham, 
MA) (Lafrenaye and Fuss, 2010).  
Oligodendrocyte morphology analysis. Oligodendrocyte morphology was 
assessed by determining the process index (total area found to be O4-positive 
minus the area occupied by the cell body) as previously described (Dennis et al., 
2008). For the generation of representative images, confocal laser scanning 
microscopy was used (Zeiss LSM 510 META NLO; Carl Zeiss Microscopy, LLC, 
Thornwood, NY). Images represent 2D maximum projections of stacks of 0.4 µm 
optical sections.  
CaMKIIβ-F-actin co-localization analysis. Cells of the oligodendroglia cell line 
CIMO (Bronstein et al., 1998) were nucelofected (Lonza Cologne GmbH, 
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Cologne, Germany) with a plasmid encoding GFP-CaMKIIβ (Okamoto et al., 
2004), and F-actin was visualized using Acti-stain 555 phalloidin (Cytoskeleton, 
Inc., Denver, CO).  
PCR and Western blot analysis. For the determination of alternative splicing 
profiles, endpoint PCR analysis was performed using the following gene-specific 
primer pairs:  
Camk2a: Forward: 5’-TGGCCACCAGGAACTTCTCCGGAGG-3’ and Reverse: 
5’-TGCGGCAGGACGACGGAGGGCGCCCCAGA-3’)  
Camk2b: Forward: 5’-CACGGAATTTCTCAGTGGGCAGACAG-3’ and Reverse: 
5’-CGCAGCTCTCACTGCAGCGGGGCCAC-3’  
Camk2g:  Forward: 5’-CGCTCCGGAAAGGGTGCCATCCTCACAACCATGC-3’ 
and Reverse: 5’-TCCGGAGCGTCTCCTCTGACTGACTGGTGCGAGG-3’  
Camk2d: Forward: 5’-CGCTCCGGAACGAGAAATTTTTCAGCAGCCAAGA-3’ 
and Reverse: 5’-TCCGGATCCTGGCTTGATGGGGACTGTTGGGGAC-3’.  
For the determination of relative mRNA expression levels, quantitative (q)RT-
PCR was performed on a CFX96 Real-Time PCR Detection System (BioRad, 
Hercules, CA) using the following gene-specific primer pairs:  
Camk2a: Forward: 5′-ACGGAAGAGTACCAGCTCTTCGAGG-3′ and Reverse: 5′-
CCTGGCCAGCCAGCACCTTCAC-3′ 
Camk2b: Forward: 5′-GTCGTCCACAGAGACCTCAAG-3′ and Reverse: 5′-
CCAGATATCCACTGGTTTGC-3′ 
Camk2g: Forward: 5′-ACGCAAGTTCAACGCCCGGAGAA-3′ and Reverse: 5′-
AGGCTCTTGGCAGCTTGCCCG-3′ 
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Camk2d: Forward: 5′-TGCCGTCTCTGAAGCACCCCA -3′ and Reverse: 5′-
ACCAAGTAATGGAAGCCCTCTTCGG-3′ 
Mbp (exon 2 containing isoforms): Forward: 5′-
ACTTGGCCACAGCAAGTACCATGGACC-3′ and Reverse: 5′-
TTGTACATGTGGCACAGCCCGGGAC-3′ 
Mpb (all isoforms): Forward: 5′-GTGACACCTCGTACACCCCCTCCAT-3′ and 
Reverse: 5′-GCTAAATCTGCTGAGGGACAGGCCT-3′ 
Plp: Forward: 5’-CCACACTAGTTTCCCTGCTCACCT-3’ and Reverse: 5’-
GGTGCCTCGGCCCATGAGTT-3’ 
Cyclophilin (as reference gene): Forward: 5′-GGAGACGAACCTGTAGGACG-3′ 
and Reverse: 5′-GATGCTCTTTCCTCCTGTGC-3’ 
For comparing the expression levels of the different Camk2 genes, R0 values 
were determined as described by Peirson et al. (2003)(Peirson et al., 2003). To 
determine relative expression levels, the ΔΔCT method was used (Livak and 
Schmittgen, 2001).  
For Western blot analysis, anti-CaMKIIβ (Life Technologies, Grand Island, 
NY) and anti-GAPDH antibodies (Millipore, Billerica, MA) were used. Bound 
antibodies were detected using enhanced chemiluminescence (ECL) in 
combination with VersaDoc imaging (BioRad Laboratories, Hercules, CA). 
Electron Microscopic Analysis. Spinal cord tissue was prepared and analyzed 
by electron microscopy as previously described (Dupree et al., 1998, Marcus et 
al., 2006, Forrest et al., 2009). Numbers of axons were determined manually per 
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field of view (14.6 µm2). G-ratios were determined as previously described 
(Dupree et al., 1998, Marcus et al., 2006, Forrest et al., 2009).  
 
Results 
Camk2b is the predominant Camk2 gene expressed by differentiating 
oligodendrocytes 
To determine the extent and alternative splicing pattern of Camk2 gene 
expression in differentiating oligodendrocytes, RT-PCR analysis was performed 
using gene-specific primer pairs spanning the variable domain (Fig. 2.1A; 
(Hudmon and Schulman, 2002b, Tombes et al., 2003). Sequence analysis of the 
resulting amplification products revealed the expression of Camk2a, b and d but 
not g. All of the three oligodendrocyte-derived genes were found to give rise to 
multiple alternatively spliced isoforms in a gene-specific fashion. Interestingly, the 
majority of Camk2b isoforms contained the alternatively spliced exon I of the 
variable domain, which has been implicated in conferring actin binding/stabilizing 
properties to CaMKIIβ (O'Leary et al., 2006).  
To determine the quantitative contribution of each of the three 
oligodendrocyte-derived Camk2 genes to overall Camk2 expression, qRT-PCR 
was performed using primer pairs located outside of the variable region and not 
affected by alternative splicing. This analysis revealed a quantitative expression 
of Camk2b > Camk2d > Camk2a (Fig. 2.1B).  
 
Inhibition of CaMKII activity restrains the morphological maturation of 
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differentiating oligodendrocytes  
The above expression analysis suggested that CaMKII and in particular CaMKIIβ 
may play an important functional role in differentiating oligodendrocytes. To 
assess such a potential role of CaMKII, differentiating oligodendrocytes were 
treated with KN-93, a membrane permeable pharmacological inhibitor of CaMKII 
activity, or its inactive derivative KN-92, and process morphology, as a measure 
for oligodendrocyte maturation, was determined (Dennis et al., 2008). Treatment 
with KN-93 caused a decreased process index (Fig. 2.2A,B) at 10 but not 1 µM. 
Such concentration-dependency is in agreement with a half-maximal inhibition of 
CaMKII at a KN-93 concentration of approximately 12 µM (Tombes et al., 1995). 
In addition, cells were treated with the membrane-permeable myristoylated-
autocamtide-2-related inhibitory peptide (MyrAIP), which mimics the CaMKII 
autoinhibitory domain (Ishida and Fujisawa, 1995) and blocks activity at 
concentrations similar to KN-93 (Easley et al., 2006, Easley et al., 2008). Such 
treatment resulted similar to the KN-93 treatment in a decreased process index 
(Fig. 2.2C). CaMKII inhibition was not found to be associated with a change in 
cell viability (KN-92: 100±9%, KN-93: 96±12%).  
Morphological maturation of oligodendrocytes occurs as a dynamic process 
that is characterized by process extension and retraction events (Kachar et al., 
1986, Fox et al., 2006a). As shown in Fig. 2.2D, process indices were found to 
be significantly decreased 2 hours after initial KN93 treatment when compared to 
the process indices found at the beginning of the treatment. Thus, the decreased 
morphological maturation seen in response to CaMKII inhibition is likely due to 
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an increase in process retraction events rather than an inhibition of process 
outgrowth.  
Retraction of cellular processes has been associated with de-stabilization of 
the actin cytoskeleton (Easley et al., 2006) Since KN-93 has been well described 
to inhibit not only CaMKII’s kinase catalytic but also CaMKIIβ’s actin 
binding/stabilizing activity (Fig. 2.2G; (Sumi et al., 1991, Lin and Redmond, 
2008), its use alone precludes an analysis of specifically CaMKIIβ’s actin 
binding/stabilizing activity. However and in support of an actin de-stabilizing 
effect of KN-93 treatment in differentiating oligodendrocytes, co-treatment with 
jasplakinolide, which specifically and rapidly blocks actin filament disassembly 
(Boggs and Wang, 2004), abolished the effect of KN-93 on the oligodendrocyte’s 
process network (Fig. 2.2E,F). No evidence for a change in cellular viability was 
noted.  
 
Downregulation of Camk2b expression restrains the morphological 
maturation of differentiating oligodendrocytes  
To determine the extent to which specifically CaMKIIβ may be involved in 
regulating the morphology of the oligodendrocyte’s process network, an siRNA-
mediated gene silencing approach was used. As shown in Fig. 2.3A,B, treatment 
with an siRNA pool to Camk2b led to a significantly decreased process index. 
Under the conditions used, siRNA treatment resulted in significantly reduced 
mRNA levels for Camk2b (Fig. 2.3C), Camk2a (60±4%) and Camk2d (74±9%). 
Use of an siRNA pool to Camk2g served as a control since expression of 
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Camk2g was undetectable in our original analysis (Fig. 2.1A). For cells treated 
with the siRNA pool to Camk2b, a reduction in CaMKIIβ protein levels could also 
be confirmed (Fig. 2.3C, inset). In neither case, was the gene-specific 
downregulation of Camk2 expression associated with an increase in mRNA 
levels for any of the other Camk2 genes (data not shown).  
In vivo, morphological maturation of oligodendrocytes is associated with well 
described changes in gene expression (Pfeiffer et al., 1993; Baumann and 
Pham-Dinh, 2001; Emery, 2010). Under experimental conditions, however, 
molecular mechanisms regulating cellular morphology may be uncoupled from 
those that regulate gene expression (Buttery and ffrench-Constant, 1999, 
Osterhout et al., 1999, Kim et al., 2006, Lafrenaye and Fuss, 2010). To 
investigate a potential role of Camk2b in regulating gene expression in 
differentiating oligodendrocytes, expression levels for mRNAs encoding the 
major myelin genes myelin basic protein (Mbp) and proteolipid protein (Plp) 
(Fulton et al., 2010) were determined. No significant differences were noted (Fig. 
2.3D). In addition, no difference was noted in the percentage of O4-positive cells 
that were also immuno-positive for MBP (siControl 52±4%, siCamk2b 49±2%).  
 
Systemic knock-out of Camk2b leads to significantly reduced myelination 
To determine the extent to which Camk2b may regulate developmental 
myelination in vivo, ventral spinal cords of systemic Camk2b knock-out (Camk2b-
/-) mice (van Woerden et al., 2009) were analyzed. As shown in Fig. 2.4A-C, the 
myelin sheath g-ratio (axon diameter divided by the diameter of the entire 
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myelinated fiber) was significantly increased at postnatal day 21 (P21) in 
Camk2b-/- spinal cords. This effect on myelin thickness persisted up to at least 58 
days of age (Fig. 2.4D,E) and was not associated with significant changes in the 
number of myelinated axons (P21: WT 39±2/14.6µm2,  Camk2b-/- 41±2/14.6µm2; 
P58: WT 35±2/14.6µm2, Camk2b-/- 35±1/14.6µm2) or apparent signs of axonal 
damage (Fig. 2.4A). In addition, no significant changes in the number of 
oligodendrocytes were noted (P21: WT 100±6%, Camk2b-/- 112±5%).  
To assess whether the mechanism by which CaMKIIβ regulates 
oligodendrocyte maturation and CNS myelination may be mediated by a non-
enzymatic activity, developmental myelination was assessed in Camk2bA303R 
mutant mice. In these mice the wild-type Camk2b gene has been replaced by the 
mutated Camk2bA303R gene (Borgesius et al., 2011). This mutation has been 
characterized to lead to a loss of calcium/calmodulin binding and kinase catalytic 
activation but to preserve the ability of CaMKIIβ to bind to and bundle/stabilize 
actin filaments (Shen and Meyer, 1999, Fink et al., 2003, O'Leary et al., 2006, Lin 
and Redmond, 2008). As shown in Fig. 2.4F,G, Camk2bA303R mutant mice were 
devoid of the deficits in myelin thickness seen in Camk2b-/- mice.   
 
Discussion  
Using in vitro tissue culture as well as in vivo knock-out and knock-in strategies, 
we identified CaMKIIβ as a critical component of the molecular mechanism 
regulating oligodendrocyte maturation and CNS myelination. More specifically, 
our data point toward a role of CaMKIIβ in regulating the oligodendrocyte’s actin 
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cytoskeleton via a mechanism that may not require its kinase catalytic activity but 
may instead involve its actin binding/stabilizing activity.  
Our in vivo analysis of developmental myelination demonstrates that CaMKIIβ 
is involved in the regulation of myelin thickness. Taken together with our in vitro 
tissue culture studies we propose that this regulatory role of CaMKIIβ is at least 
in part mediated by an oligodendrocyte-autonomous mechanism. In support of 
this idea, astrocytes are considered to not express considerable levels of 
Camk2b (Takeuchi et al., 2000, Vallano et al., 2000). In addition, CaMKIIβ 
protein levels in axons located within the ventral spinal cord have been described 
to be undetectable or very low (Terashima et al., 1994). Thus, systemic Camk2b 
knock-out is unlikely to cause a predominantly axon-mediated effect on 
myelination within the CNS region investigated here. 
The lack of a myelination deficit in the spinal cord of Camk2bA303R mutant 
mice strengthens the idea of a functional role of CaMKIIβ as an actin regulatory 
protein and via its actin binding activity. In neuronal dendritic spines, CaMKIIβ, 
via its actin binding activity, is thought to stabilize the actin cytoskeleton and thus 
overall spine shape. At the same time, however, calcium signaling has been 
implicated in promoting release of CaMKIIβ from the actin cytoskeleton and to 
thereby open a time window during which actin cytoskeleton remodeling events 
are favored (Okamoto et al., 2007; Okamoto et al., 2009). In analogy, 
oligodendrocyte maturation and CNS myelination may be regulated by CaMKIIβ-
mediated alternating cycles of actin cytoskeleton stabilization and de-
stabilization/remodeling. As CaMKIIβ-mediated regulation is dependent on 
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calcium signaling events, it is worth mentioning that an increase in calcium 
signaling has been reported to stimulate oligodendrocyte process outgrowth and 
thus morphological maturation (Yoo et al., 1999). Furthermore, it has been 
recently shown that balanced activation and de-activation of the actin filament 
severing and depolymerizing factor cofilin regulates Schwann cell function during 
peripheral nervous system myelination (Sparrow et al., 2012). This finding 
supports the idea that efficient myelination may be critically dependent on a well-
balanced equilibrium between dynamic remodeling and kinetic stability of the 
actin cytoskeleton. Future studies will, however, be necessary to better define the 
role of CaMKIIβ in regulating the actin cytoskeleton during oligodendrocyte 
maturation and CNS myelination.  
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Figure 2.1 In differentiating oligodendrocytes Camk2b is the predominantly 
expressed Camk2 gene. A, Alternative splicing profile of oligodendrocyte-derived 
Camk2 genes as determined by RT-PCR analysis. Conserved non-alternatively 
spliced “linker” exons within the variable region are depicted as black boxes 
labeled with the roman numerals II and VII. Alternatively spliced exons are 
depicted as white boxes labeled with roman numerals. Lines indicate alternative 
splicing events. P1 and P2 indicate the locations of the two primers used for RT-
PCR amplification. B, Camk2 mRNA expression levels as determined by qRT-
PCR analysis. For the bar graph, total Camk2 mRNA levels were set to 100% 
and the values for each of the three genes were adjusted accordingly. Data 
represent means ± SEM (n = 3 independent experiments, *p<0.05, Student’s t-
test).  
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Figure 2.2 Inhibition of CaMKII activity in differentiating oligodendrocytes 
restrains the establishment of an expanded process network. A,F, 
Representative images of differentiating oligodendrocytes immunostained with 
the O4 antibody and treated for 6 hours as indicated. Scale Bars: 20 µm. B-E, 
Bar graphs representing quantitative analyses of process indices as described by 
Dennis et al. (2008). Cells in B,D,E were treated with the pharmacological 
CaMKII inhibitor KN-93 or its inactive derivative KN-92 as control, while cells in C 
were treated with the myristoylated autoinhibitory CaMKII peptide (Myr-AIP) or a 
myristoylated control peptide (CtrlP). Cells in E were co-treated with the actin 
stabilizing peptide jasplakinolide (10 µM) where noted and analyzed after 6 hours 
of treatment. Otherwise, final concentrations and duration of treatments are 
indicated within the bar graphs. In B,C,E experimental conditions were compared 
to control-treated cells cultured for an equivalent period of time. In D, 
experimental conditions were compared to control-treated cells at time-point 0. 
For all bar graphs, the mean values for control cells were set to 100% (horizontal 
grey line) and experimental values were calculated accordingly. At least 25 cells 
per condition and experiment were analyzed in three independent experiments (= 
total of at least 75 cells per condition). Data represent experimental means ± 
SEM (*p<0.05, Student’s t-test). G, Representative images of CIMO cells 
transfected with a plasmid encoding GFP-CaMKIIβ and stained for F-actin 
(phalloidin). Scale Bars: 5 µm. 
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Figure 2.3 Knock-down of Camk2b expression in differentiating oligodendrocytes 
restrains the establishment of an expanded process network. A, Bar graph 
representing quantitative analyses of process indices (Dennis et al., 2008) upon 
siRNA-mediated knock-down of individual Camk2 genes as indicated. The mean 
value for cells treated with the control siRNA pool was set to 100% (horizontal 
grey line) and experimental values were calculated accordingly. At least 25 cells 
per condition and experiment were analyzed in four independent experiments (= 
total of at least 100 cells per condition). Data represent experimental means ± 
SEM (*p<0.05, Student’s t-test). B, Representative images of differentiating 
oligodendrocytes immunostained with the O4 antibody and treated with a control 
(siControl) or Camk2b-specific (siCamk2b) siRNA pool. Scale Bars: 20 µm. C, 
Bar graph depicting the Camk2b mRNA level upon siRNA-mediated knock-down 
of Camk2b. The mean value for cells treated with the control siRNA pool was set 
to 100% (horizontal grey line) and the experimental value was calculated 
accordingly. The experimental mean ± SEM (*p<0.05, one sample t-test) is 
shown. The inset depicts a representative Western blot. CaMKIIβ and GAPDH 
protein levels are shown for cells treated with a control (siControl) or Camk2b-
specific (siCamk2b) siRNA pool. D, Bar graph depicting Mbp (total and exon 2 
containing) and Plp mRNA levels upon siRNA-mediated knock-down of Camk2b. 
The mean value for cells treated with the control siRNA pool was set to 100% 
(horizontal grey line) and experimental values were calculated accordingly. Data 
represent experimental means ± SEM (*p<0.05, one sample t-test). 
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Figure 2.4  Knock-out of Camk2b leads to an increase in the g-ratio (decrease in 
the thickness) of the myelin sheath, while myelination appears unaffected in 
Camk2A303R mutant mice. A, inset in F, Representative electron micrographs of 
the ventral spinal cord of 21-day-old (P21) wild-type (WT) and Camk2b knock-out 
(Camk2b-/-) mice (in A) or Camk2A303R mutant mice (in F). Scale bars: 1mm. 
B,D,F, Scatter plots depicting g-ratios versus axon diameters for P21 Camk2b-/- 
(B), adult Camk2b-/- (D) or P21 Camk2A303R (F) (black filled circles) and WT 
littermate (red open circles) ventral spinal cords. The lines represent linear fits to 
pooled data from all mice for each genotype. 100 axons per animal were 
measured and 3 animals per genotype were analyzed. C,E,G, Bar graphs 
depicting average slopes (g-ratio versus axon diameter) and average g-ratios 
from individual animals (n=3). Stars indicate statistically significant differences 
between wild-type and knock-out/mutant mice (*p < 0.05, Student’s t-test).  
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Introduction to Glutamate and Glutamate Transporters 
 
 
Glutamate transporters and receptors in oligodendrocytes 
 Glutamate is a major excitatory neurotransmitter found in the CNS that 
governs a wide variety of activities from normal brain function to the development 
of cells in the CNS (Gallo and Ghiani, 2000, Kukley et al., 2007, Bakiri et al., 
2009, Hamilton et al., 2010). During development, there are multiple sources of 
glutamate released in the CNS that could affect cells of the oligodendrocyte 
lineage. These sources range from cells such as unmyelinated axons and 
astrocytes to extracellular lipids and proteins such as prostaglandins and 
neuropeptides respectively (Parpura et al., 1994, Gallo et al., 1996, Gallo and 
Ghiani, 2000, Bezzi and Volterra, 2001, Kukley et al., 2007, Ziskin et al., 2007, 
Nave and Trapp, 2008, Bakiri et al., 2009, Hamilton et al., 2010). Glutamate 
release and signaling in oligodendrocytes are key in many aspects of 
oligodendrocyte progenitor migration, proliferation, and differentiation (Barres 
and Raff, 1993, Gallo et al., 1996, Ziskin et al., 2007, DeSilva et al., 2009).  
 In general, glutamate signals through the activation of specific glutamate 
receptors. These receptors are divided into metabotropic and ionotropic 
receptors. Metabotropic glutamate receptors are further subdivided into classes 
based on activation or inhibition of downstream proteins such as phospholipase 
C and adenylate cyclase (Bakiri et al., 2009, Martinez-Lozada et al., 2011). 
However, metabotropic receptors seem to be downregulated early on in 
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oligodendrocyte differentiation and maturation (Deng et al., 2004, Luyt et al., 
2007).  
 Examples of ionotropic receptors are N-methyl-D-aspartate (NMDA), α-
amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPA), and 
Kainate receptors. All types of ionotropic receptors are expressed during 
oligodendrocyte differentiation. Although NMDA receptors and AMPA receptors 
are usually associated with neurons, they also play a critical role in mediating 
glutamate signaling and excitotoxicity in oligodendrocytes (Verkhratsky and 
Kirchhoff, 2007). 
 Oligodendrocytes express AMPA receptors in immature oligodendrocytes 
and mature oligodendrocytes throughout the brain (Gallo and Ghiani, 2000, 
Verkhratsky and Steinhauser, 2000, Verkhratsky and Kirchhoff, 2007). Activation 
of AMPA receptors in oligodendrocytes produces substantial Ca2+ influx and an 
increase in cytosolic Ca2+ signals in culture and acute brain slices (Burnashev et 
al., 1992; Verkhratsky and Kirchhoff, 2007).  
NMDA receptors are expressed in oligodendrocytes in the corpus 
callosum, cerebellum, and optic nerve (Karadottir et al., 2005, Salter and Fern, 
2005, Micu et al., 2006).  They are glutamate-gated ion channels formed by 
oligomeric subunits (Wong, 2006), consisting of a NR1 subunit and various types 
of NR2 subunits. Both of these subunit types have been found in 
oligodendrocytes (Wong, 2006).  In particular, the NR2 subunits NR2A, NR2B, 
NR2C, and NR2D are expressed in oligodendrocytes (Wong, 2006). 
Quantification of the subunit population in oligodendrocytes shows that NR1, 
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NR2C, and NR3A are the most abundant subunits in the optic nerve.  NR2B 
subunits are present, although not as abundant (Wong, 2006).  
With regard to their subcellular localization, NMDA receptors are found 
primarily in the cellular process of oligodendrocytes where they are thought to 
mediate responses that develop in the distal processes (Salter and Fern, 2005, 
Micu et al., 2006). They are much less prominent in the soma of 
oligodendrocytes (Micu et al., 2006; Salter and Fern, 2005).  
 By using electrophysiological recordings, research has shown the activation 
of NMDA receptors during all stages of the oligodendrocyte lineage (Karadottir et 
al., 2005).  Although the function of NMDA receptors in oligodendrocytes is 
unclear, NMDA receptors are suggested to play a role in the targeting and 
interaction of the axon with the oligodendrocyte process (Salter and Fern, 2005; 
Verkhratsky and Kirchhoff, 2007; Wong, 2006).  
 Contradictory to the role NMDA receptors play during development, studies 
have shown that oligodendrocyte specific knockout of NMDA receptors NR1 
subunit (which in turn functionally inactivates NMDA receptors) leads to normal 
physiology, morphology, numbers, and myelination of oligodendrocytes (De 
Biase et al., 2011, Guo et al., 2012). This brings into question the importance of 
NMDA receptors during development. De Biase et.al (2011) observed an 
increased expression of AMPA receptors after NMDA knockout. This observed 
increase in AMPA receptors could provide a compensatory response to the 
NMDA knockout (De Biase et al., 2011).  In addition to a potential role during 
development, activation of NMDA receptors has also been found to lead to rapid 
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cell death during ischemic attacks by mediating excitotoxicity (Salter and Fern, 
2005; Verkhratsky and Kirchhoff, 2007; Wong, 2006). Thus, the functional role of 
NMDA receptors may be more prominent under pathological conditions than 
during development.  
 Glutamate can activate other types of glutamate responsive transmembrane 
proteins.  These proteins belong to a family of electrogenic sodium-dependent 
transporters. These transporters have been well characterized to remove 
glutamate from the extracellular environment (Domercq et al., 1999, DeSilva et 
al., 2009, Martinez-Lozada et al., 2011). The glutamate transporter family has 
five genes in mammals: excitatory amino acid transporters 1-5 (Eaat1-Eaat5); 
however, oligodendrocytes have been characterized to express three of these 
genes: Eaat1-Eaat3.  These subtypes are also named glutamate aspartate 
transporter (GLAST), glutamate transporter 1 (GLT1), and EAAC1 respectively. 
(Domercq et al., 1999, DeSilva et al., 2009, Martinez-Lozada et al., 2011, Lee et 
al., 2012).  
 Several studies have examined the expression and the functional role of 
sodium-dependent glutamate transporters as they relate to oligodendrocyte 
development.  A study using transgenic mice for each promoter of GLT1 and 
GLAST focused on the cellular identification of these glutamate transporters in 
different cell types of the CNS. The study used reporter mice and showed that 
GLT1 promoter activity is in the adult and for the most part restricted to 
astrocytes. GLAST promoter activity was, however, also seen in 
oligodendrocytes in the white matter of the spinal cord, striatum, and corpus 
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callosum (Regan et al., 2007). Furthermore, this study demonstrated by 
functional uptake experiments that oligodendrocytes likely express more than 
one glutamate transporter (Regan et al., 2007). This was furthermore 
demonstrated in a later study showing that all three transporters are found in rat 
oligodendrocytes in vitro. Not only were they found present in oligodendrocytes, 
they were also found to be functionally active with EAAC1 apparently possessing 
the highest uptake activity (DeSilva et al., 2009). Based on these studies, the 
functional activity of these transporters appeared to be similar in the uptake 
capacity and the affinity for glutamate as seen for astrocytes (DeSilva et al., 
2009). In several studies, protein expression of each transporter was seen at 
varying stages of the oligodendrocyte lineage (DeSilva et al., 2009). Interestingly, 
GLT1 expression seems to be upregulated as oligodendrocyte development 
progresses from pre-oligodendrocytes to mature oligodendrocytes (DeSilva et al., 
2009). However, in vivo, there seems to be a downregulation of GLT1 in more 
mature (P20) rat corpus callosum. This is in contrast to slight differences in 
expression profiles when comparing cells in culture to in vivo tissues. All three 
subtypes of transporters are expressed by oligodendrocytes (Domercq et al., 
1999, DeSilva et al., 2009, Martinez-Lozada et al., 2011).  
In addition to glutamate clearance, research suggests that glutamate 
transporters could play a role in downstream signaling mechanisms. Activation of 
glutamate transporters allows for glutamate to enter the cell through the 
transporter’s pore. Along with the entrance of glutamate, 3 Na+ ions also pass 
through the transporter and enter the cell. This influx of sodium can activate the 
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reverse mode of the Na+/Ca2+ exchanger (NCX) (Martinez-Lozada et al., 2011, 
Boscia et al., 2012b). This exchanger then takes the 3 Na+ ions out in exchange 
for Ca2+. Thus, activation of glutamate transporters can induce a Ca2+ influx into 
the cell (Martinez-Lozada et al., 2011, Boscia et al., 2012b). This Ca2+ influx has 
been shown in Bergmann glia cells to initiate signaling cascades (Martinez-
Lozada et al., 2011).  Oligodendrocytes express NCX1 and NCX3 and their 
expression seems to be developmentally regulated with NCX1 being 
downregulated and NCX3 being upregulated as oligodendrocytes mature (Boscia 
et al., 2012b) (Figure 3.1). Furthermore, the expression of NCX3 seems to be 
crucial for proper myelination and oligodendrocyte development (Boscia et al., 
2012b). Thus the importance of glutamate transporters and its association with 
NXC may be critical for proper oligodendrocyte development.  
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Figure 3.1: The transport of glutamate through the glutamate transporter is 
coupled to the Na+/Ca2+ exchanger regulating the Na+ efflux in exchange for Ca2+ 
influx, which can provide localized Ca2+ signaling.  Adapted from (Martínez-
Lozada et al., 2011). 
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CHAPTER 4 
 
Activation of Sodium-dependent Glutamate Transporters regulates 
Oligodendrocyte Maturation via signaling through CaMKIIβ’s Actin 
Binding/Stabilizing Domain 
 
(This chapter was submitted to Glia for peer review in July 2013. This work was 
an equal contribution between Zila Martinez Lozada and myself. ) 
 
 
 
INTRODUCTION 
Glutamate, the major excitatory amino acid, mediates a wide variety of cellular 
responses in the developing and adult central nervous system (CNS), not only by 
affecting signal transduction in neurons but also by regulating glia cells, including 
the myelinating cells of the CNS, oligodendrocytes (Bakiri et al., 2009, 
Kolodziejczyk et al., 2010). Interestingly, the primary mode of glutamate release 
affecting differentiating cells of the oligodendrocyte lineage during development 
and under physiological conditions appears to be vesicle exocytosis along 
unmyelinated axons (Kukley et al., 2007, Ziskin et al., 2007), even though 
glutamate release from active axons by reversal of glutamate uptake has also 
been proposed (Kriegler and Chiu, 1993). The prominent release of glutamate 
from unmyelinated axons raises the possibility that glutamate, in addition to 
mediating signaling events at synaptic junctions between NG2-positive glial 
progenitors and axons, may be able to trigger transient cellular responses in 
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differentiating oligodendrocytes that are involved in the regulation of 
oligodendrocyte maturation and myelination.  
Cells of the oligodendrocyte lineage have been described to express 
members of all of the three major glutamate-responsive transmembrane protein 
families, namely ionotropic and metabotropic glutamate receptors as well as 
sodium-dependent glutamate transporters (Kolodziejczyk et al., 2010, Matute, 
2011). Out of these, metabotropic glutamate receptors have been found 
downregulated as oligodendrocytes differentiate (Deng et al., 2004, Luyt et al., 
2006), and ionotropic glutamate receptors have been primarily implicated in 
mediating excitotoxicity (Matute, 2011). Thus, sodium-dependent glutamate 
transporters emerge as good candidates for mediating glutamate-evoked 
responses related to the maturation of differentiating oligodendrocytes, i.e. of 
cells that are located in the vicinity of axonal segments to be myelinated and that 
are beyond the progenitor stage. Of the known five mammalian sodium-
dependent glutamate transporters, also known as excitatory amino acid 
transporters (EAAT) or members of the solute carrier family 1 (SLC1), three have 
been found expressed by cells of the oligodendrocyte lineage, namely GLAST 
(EAAT1, SLC1A3), GLT-1 (EAAT2, SLC1A2) and EAAC1 (EAAT3, SLC1A1) 
(Domercq and Matute, 1999, Regan et al., 2007, Arranz et al., 2008, DeSilva et 
al., 2009, Kukley et al., 2010, Lee et al., 2012). These transporters have been 
well characterized to remove the excitatory amino acid glutamate from the 
extracellular environment (Danbolt, 2001, O'Shea, 2002, Beart and O'Shea, 
2007). However, there is increasing evidence for a role of sodium-dependent 
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glutamate transporters beyond extracellular glutamate clearance (Chen et al., 
2006, Martinez-Lozada et al., 2011, Lopez-Colome et al., 2012). 
Interestingly, signaling initiated by the activation of sodium-dependent 
glutamate transporters has been proposed to activate calcium/calmodulin-
dependent kinase type II (CaMKII) (Martinez-Lozada et al., 2011), and one of the 
four CaMKII genes, namely CaMKIIβ, has recently been implicated in the 
regulation of oligodendrocyte maturation and myelination (Waggener, 2013 
#1214). More specifically, CaMKIIβ has been proposed to promote the 
morphological aspects of oligodendrocyte maturation, which are to a large extent 
regulated by changes in the cellular cytoskeleton (Bauer et al., 2009), primarily 
via its actin binding/stabilizing domain rather than its well-known kinase catalytic 
domain (Waggener et al., 2013). Thus and based on the above observations, we 
investigated here a possible role of a glutamate transporter-CaMKIIβ-actin 
cytoskeleton axis in the regulation of the morphological aspects of 
oligodendrocyte maturation.  
  
MATERIALS AND METHODS 
Animals 
Sprague–Dawley female rats with early postnatal litters were obtained from 
Harlan Laboratories, Inc. (Indianapolis, IN). All animal studies were approved by 
the Institutional Animal Care and Use Committee at Virginia Commonwealth 
University. 
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Antibodies 
Supernatants from cultured hybridoma cells (clone A2B5; ATCC, Manassas, VA) 
were used for immunopanning. Anti-GLAST, anti-GLT-1, anti-EAAC1 (Abcam, 
Cambridge, MA), anti-CaMKII, anti-pCaMKII T286/7  (Cell Signaling Technology, 
Inc. Danvers, MA) and anti-GAPDH (EMD Millipore, Billerica, MA) antibodies in 
combination with horseradish peroxidase (HRP)-labeled secondary antibodies 
(Vector Laboratories, Burlingame, CA) were used for Western blot analysis. 
Antibodies specifically recognizing pCaMKIIβ S371 were generated and 
characterized by us. Supernatants from cultured hybridoma cells (clone O4; gift 
from S.E. Pfeiffer) and anti-MBP antibodies (EMD Millipore, Billerica, MA) were 
used for immunocytochemistry to identify post-migratory, premyelinating 
oligodendrocytes (Sommer and Schachner, 1981, Bansal et al., 1989) and later 
stages of the oligodendrocyte lineage, respectively. Alexa 488- or Alexa 564-
conjugated antibodies (Life Technologies, Grand Island, NY) were used as 
secondary antibodies.  
 
Cell Culture 
Primary rat oligodendrocyte progenitors were isolated from postnatal day 3 (P3) 
rat brains by A2B5 immunopanning (Lafrenaye and Fuss, 2011, Barres, 1992 
#57). Oligodendrocyte progenitors were either used directly in plasmid 
nucleofection experiments or plated onto fibronectin (10 µM/mL)-coated tissue 
culture dishes or glass coverslips. Plated oligodendrocyte progenitors were then 
cultured in serum-free differentiation medium (DMEM containing 40 ng/ml tri-
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iodo-thyronine (T3; Sigma, St Louis, MO) and 1x N2 supplement (Life 
Technologies Corp., Grand Island, NY); DMEM/T3/N2). In siRNA-mediated gene 
silencing experiments, differentiating oligodendrocytes were transfected with 
siRNAs 24h after plating. Otherwise, plated oligodendrocyte progenitors were 
allowed to differentiate for 48h. Under these conditions, the majority of cells 
represented post-migratory, premyelinating oligodendrocytes as they expressed 
the O4 antigen (Sommer and Schachner, 1982, Warrington et al., 1993)(data not 
shown). Such populations of differentiating oligodendrocytes were then either 
directly analyzed or treated with L-glutamate (Glu; R&D Systems, Inc. 
Minneapolis, MN), D-aspartate (Asp; R&D Systems, Inc. Minneapolis, MN), the 
competitive, non-transportable blocker of excitatory amino acid transporters 
TBOA (R&D Systems, Inc. Minneapolis, MN), the membrane permeable 
pharmacological inhibitor of CaMKII activity KN-93 or the inactive derivative of 
KN-93, KN-92 (EMD Millipore, Billerica, MA) as indicated. In the case of dual 
treatments, TBOA, KN-93 or KN-92 were added 30 min prior to the application of 
L-glutamate or D-aspartate. Cells were analyzed 6 hours after addition of L-
glutamate or D-aspartate unless stated otherwise.  
Cells of the immortalized mouse oligodendroglial cell line CIMO were cultured 
in DMEM/5% FCS/1 µg/mL interferon-γ (EMD Millipore, Billerica, MA) at 33 °C 
(Bronstein et al., 1998) and then used in plasmid nucleofection experiments. 
 
Quantitative (q)RT-PCR Analysis 
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Total RNA was isolated from oligodendrocyte cultures using the RNeasy Micro 
Kit (QIAGEN Inc., Valencia, CA). Purified RNA samples were quantified using the 
Nanodrop ND-1000 (Nanodrop Inc., Wilmington, DE) and oligo(dT)/random 
hexamer-primed cDNAs were synthesized using the Omniscript RT kit (QIAGEN 
Inc., Valencia, CA). qRT-PCR was performed on a CFX96 Real-Time PCR 
Detection System (Bio-Rad, Hercules, CA) using the iQ SYBR Green Supermix 
(Bio-Rad, Hercules, CA) and the following gene-specific primer pairs:  
Glast: forward (5′-AGCCTGGGGTGTCTTCCACCA-3′), reverse (5′-
ACCACAGCCTTGCACTTCAGTGTCT-3′);  
Glt-1: forward (5′-TGGCGGCTCCCATCCACCCT-3′), reverse (5′-
GGCGGCCGCTGGCTTTAGCA-3′);  
Eaac1: forward (5′-GCCCACGAGCTCGGGATGCG-3′), reverse (5′-
CACGATGCCCAGTACCACGGC-3′).  
Ppia (reference gene):  forward: (5′-GGAGACGAACCTGTAGGACG-3′) and 
reverse: (5′-GATGCTCTTTCCTCCTGTGC-3’) 
Pgk1 (reference gene): forward: (5’-ATGCAAAGACTGGCCAAGCTAC-3’) 
and reverse: (5’-AGCCACAGCCTCAGCATATTTC -3’) 
PCR conditions were as follows: 95°C for 3 min followed by 40 cycles of 95°C 
for 15s, 58°C for 30s, and 95°C for 10s. For comparing the expression levels of 
the different genes, R0 values were determined as described by (Peirson et al., 
2003). To determine relative expression levels the ΔΔCT method was used (Livak 
and Schmittgen, 2001). 
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Western blot analysis 
Cells were homogenized in lysis buffer (150 mM NaCl, 10 mM KCl, 20 mM 
HEPES (pH 7.0), 1 mM MgCl2, 20% Glycerol, 1% Triton X-100) including the 
complete protease and phosphatase inhibitor cocktail (Thermo Scientific, 
Rockford, IL). Protein concentrations were determined using the micro BSA 
protein assay kit (Thermo Scientific, Rockford, IL). 12µg of protein were used for 
Western blot analysis (except when using anti-GLAST antibodies, in which case 
30µg of protein were used). All samples were diluted 1:2 in Laemmli Sample 
Buffer (Bio-Rad, Hercules, CA) and denatured by a 5 min incubation at 95°C. 
Proteins were resolved on 10% SDS–polyacrylamide gels (Mini-Protean TGX 
Gels, Bio-Rad, Hercules CA) and then transferred to Immobilon-P PVDF 
membranes (EMD Millipore, Billerica, MA). Membranes were incubated in 5-10% 
fat-free milk powder in TBS-T (10 mM Tris–HCl, pH 7.5, 0.15 M NaCl, 0.2% 
Tween 20) for 60 min to block the excess of non-specific protein binding sites. 
Membranes were then incubated overnight at 4°C with primary antibodies as 
indicated. Bound antibodies were detected using HRP-conjugated secondary 
antibodies in combination with the ECL Prime Western blotting detection reagent 
(GE Healthcare Life Sciences, Piscataway, NJ). Chemiluminescent signals were 
detected by exposure of photographic film (Kodak BioMax MR, Eastman Kodak 
Company, Rochester, NY) and quantified by densitometry using the ImageJ 
software package (Abramoff et al., 2004).  
 
Immunocytochemistry  
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For immunocytochemistry using O4 hybridoma supernatants, cells were fixed in 
a solution containing 4% paraformaldehyde, nonspecific binding sites were 
blocked using a solution of 10% FCS in DMEM and cells were incubated with the 
supernatant (1:1 diluted in 10%FCS/DMEM) overnight. For immunocytochemical 
detection of MBP, cells were fixed in a solution containing 4% paraformaldehyde 
and then permeabilized using 0.5% Triton X-100/0.4 M sucrose in PBS. 
Subsequently, cells were incubated for 30 min in 10% FCS/DMEM and then 
overnight with anti-MBP antibodies (SMI99; Covance, Princeton, NJ) (1:250 
diluted in 10% FCS/DMEM). Primary antibodies were detected using Alexa 488- 
or Alexa 564-conjugated secondary antibodies (Life Technologies Corp., Grand 
Island, NY) (1:250 diluted in PBS) and nuclei were counterstained using Hoechst 
(1 µg/mL; EMD Millipore, Billerica, MA).  
To visualize the actin cytoskeleton, cells were fixed in a solution containing 
4% paraformaldehyde, 0.5 % glutaraldehyde and 0.4M sucrose and then 
incubated with Acti-stain 555 phalloidin (Cytoskeleton, Inc., Denver, CO).  
 
siRNA-mediated Gene Silencing 
Differentiating oligodendrocytes were transfected with ON-TARGETplus siRNA 
SMARTpools directed against rat Glast, Glt-1 or Eaac1 (Thermo Fisher Scientific 
Inc., Pittsburg, PA) using Lipofectamine 2000 (Life Technologies Corp., Grand 
Island, NY). As control, an ON-TARGETplus non-targeting siRNA pool (Thermo 
Fisher Scientific Inc., Pittsburg, PA) was used. Transfection medium containing 
siRNA-Lipofectamine complexes was replaced with serum-free differentiation 
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medium (DMEM/T3/N2) after 3h and cells were cultured for an additional 72h. 
Knock-down of gene expression was assessed by qRT-PCR and Western blot 
analysis.  
 
Process Morphology Analysis 
Oligodendrocyte morphology was analyzed as previously described (Dennis et 
al., 2008).  Briefly, oligodendrocytes were immunostained using O4 hybridoma 
cell supernatants. Images of approximately 30 cells were taken randomly for 
each treatment group in each experiment (n≥3) using an Olympus BX51 inverted 
fluorescent microscope (Olympus America Inc., Center Valley, PA). IP Lab 
imaging software (BD Biosciences Bioimaging, Rockville, MD) was used to 
determine process index (total O4 imunopositive area minus the cell body) and 
network area (total area within the radius of the O4 immunopositive process 
network minus the cell body). For the bar graphs representing network area, the 
mean value for cells cultured under control conditions was calculated. This mean 
value was set to 100% and adjusted, i.e. normalized, values for all cells were 
averaged for each experimental condition. For the generation of representative 
images, confocal laser scanning microscopy was used (Zeiss LSM 510 META 
NLO; Carl Zeiss Microscopy, LLC, Thornwood, NY). Images represent 2D 
maximum projections of stacks of 0.4 µm optical sections.  
 
Cell Count Analysis  
Images of four fields were taken with a 20x objective from each coverslip (three 
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coverslips per condition) using an Olympus BX51 fluorescence microscope 
equipped with an Olympus DP72 CCD camera (Olympus America Inc., Center 
Valley, PA). The number of Hoechst-positive and MBP immuno-positive 
oligodendrocytes was then determined using the Cell Counter plugin to the 
ImageJ software package (Abramoff et al., 2004). 
 
Plasmid Nucleofection 
A2B5 immunopanned oligodendrocyte progenitors or CIMO cells were 
nucleofected (Lonza Cologne GmbH, Cologne, Germany) with the following 
constructs: a plasmid encoding eGFP-CaMKIIβ (Okamoto et al., 2004), a plasmid 
encoding eGFP-CaMKIIβallA in which all serine and threonine residues located 
within the variable domain (aa 317-396) were replaced with alanine, a plasmid 
encoding eGFP-CaMKIIβallD in which all serine and threonine residues located 
within the variable domain (aa 317-396) were replaced with aspartic acid, and a 
control plasmid encoding eGFP alone. All plasmids had the same plasmid 
backbone derived from the eukaryotic expression vector pEGFP-C1 (Clontech 
Laboratories, Inc., Mountain View, CA).  
 
Intracelullar Calcium Measurement 
Intracellular calcium concentrations were determined in principle as previously 
described (Grynkiewicz et al., 1985). Briefly, differentiating oligodendrocytes 
were loaded with the calcium indicator fura-2 AM ester (2.5µM) and pluronic 
(0.01%) (Life Technologies Corp., Grand Island, NY) in differentiation medium for 
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30 min at 37°C. Cells were washed and incubated in differentiation medium for 
an additional 30 min at 37°C. Ratiometric calcium measurements were made at 
340 and 380 nm excitation and 510-520 nm emission wavelengths with cells 
cultured in differentiation medium (unless mentioned otherwise) using a Zeiss 
Observer.Z1 microscope in combination with the Axio VisionRel 4.8 software 
package (Carl Zeiss Microscopy, LLC, Thornwood, NY). Measurements were 
made before and after the application of the indicated compounds. To calculate 
intracellular free calcium concentrations (in nM), a calibration curve (Calcium 
Calibration Buffer Kit, Life Technologies Corp., Grand Island, NY) was used.  
 
Statistical Analysis 
For statistical analysis the GraphPad Prism software (GraphPad Software, Inc., 
La Jolla, CA) was used. In the case of two or more groups of data composed of 
variable values, two-tailed Student’s t-tests or Kruskal–Wallis one-way analyses 
of variance (ANOVA) combined with post hoc Dunn’s or Student–Newman–Keuls 
tests were performed. When comparing a single control group with experimental 
groups of data, ANOVA with post hoc Dunnett tests were used. In the case data 
were compared to a set control value (1 or 100%) lacking variability, one-sample 
t-tests were used (Skokal and Rohlf, 1995, Dalgaard, 2008).  
 
 
RESULTS 
Sodium-dependent glutamate transport, mediated primarily by GLAST and 
GLT-1, promotes the morphological maturation of differentiating 
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oligodendrocytes.  
As introduced above, the sodium-dependent glutamate transporter genes Glast, 
Glt-1and Eaac1 have previously been described to be expressed by cells of the 
oligodendrocyte lineage. To confirm such expression in our culture system, qRT-
PCR analysis was performed and revealed relative mRNA expression levels of 
45±5%, 31±6%, and 12±5% for Glast, Glt-1 and Eaac1, respectively (Fig. 4.1A). 
Using Western blot analysis the expression of the three sodium-dependent 
glutamate transporters in differentiating oligodendrocytes could be further 
validated (Fig. 4.1B). To assess a potential role of sodium-dependent glutamate 
transport beyond extracellular glutamate clearance in differentiating 
oligodendrocytes, these cells were treated with 100 mM L-glutamate in 
combination with TBOA, a competitive and non-transportable inhibitor of sodium-
dependent glutamate transport (Shimamoto et al., 1998, Shigeri et al., 2001), and 
morphological aspects of oligodendrocyte maturation were assessed by 
determining the cells’ network areas and process indices (Dennis et al., 2008). 
Increases in both parameters were observed upon treatment with L-glutamate 
(Fig. 4.2A,B and data not shown). This maturation-promoting effect of L-
glutamate was seen as early as 2 hours and up to 6 hours of treatment (Fig. 
4.2C). Importantly, it could be blocked by pre-treatment with TBOA and was thus 
found to be dependent on the activity of sodium-dependent glutamate 
transporters (Figs. 4.2A,B). It is of note that in agreement with previous studies, 
no obvious effects on cell survival were noted in the presence of the glutamate 
and TBOA concentrations used here and within the time frames analyzed (Deng 
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et al., 2006) and data not shown).  
To further substantiate that sodium-dependent glutamate transporters play a 
predominant role in the observed maturation-promoting effect exerted by L-
glutamate, the naturally occurring amino-acid D-aspartate was used as a 
glutamate-equivalent agonist. As L-glutamate, D-aspartate is efficiently taken up 
through the sodium-dependent glutamate transporter system (Davies and 
Johnston, 1976, Danbolt and Storm-Mathisen, 1986, Kanai and Hediger, 1992, 
Pines et al., 1992, Palacin et al., 1998), and it is then endogenously metabolized 
(Schell et al., 1997). In contrast to L-glutamate, however, D-aspartate is known to 
not activate non-NMDA receptor iononotropic glutamate receptors (Domercq et 
al., 2005, Errico et al., 2008), thus eliminating potential confounding effects due 
to an activation of AMPA/kainate receptors. As shown in Fig. 4.2D, the effect of 
D-aspartate on the oligodendrocyte’s process network was comparable to the 
effect seen upon treatment with L-glutamate (compare Figs. 4.2B and D).  
It has been well demonstrated that morphological maturation of 
oligodendrocytes occurs during development concurrently with changes in gene 
expression (Pfeiffer et al., 1993, Baumann and Pham-Dinh, 2001, Emery, 2010). 
Under experimental conditions, however, molecular mechanisms regulating 
cellular morphology may be uncoupled from those that regulate gene expression 
(Buttery and ffrench-Constant, 1999, Osterhout et al., 1999, Kim et al., 2006, 
Lafrenaye and Fuss, 2011, Waggener et al., 2013). Thus and to assess a 
potential role of L-glutamate and the activity of sodium-dependent glutamate 
transporters on myelin gene expression, potential changes in myelin basic 
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protein (MBP) expression were assayed using immunocytochemistry. As shown 
in Fig. 4.2E, no significant differences in the number of MBP-positive cells were 
noted, thus suggesting that the sodium-dependent glutamate transporter-
mediated effect on oligodendrocyte maturation is primarily associated with the 
morphological aspects of this process.  
As shown in Fig. 4.1, differentiating oligodendrocytes express more than one 
of the known sodium-dependent glutamate transporter genes. To evaluate the 
role of individual transporter genes in the L-glutamate-mediated maturation-
promoting effect observed here, differentiating oligodendrocytes were transfected 
with siRNA pools specifically silencing Glast, Glt-1 or Eaac1 expression. Knock-
down of gene expression was confirmed by Western blot analysis, which 
revealed a specific reduction in transporter protein levels of at least 70% (Fig. 
4.S1). Importantly, for none of the down-regulated genes a compensatory up-
regulation of any of the other two transporter genes was noted (Fig. 4.S1). As 
shown in Fig. 4.2F, knock-down of either Glast or Glt-1 expression was found to 
eliminate the effect of L-glutamate on the oligodendrocyte’s process network. For 
the sodium-dependent glutamate transporter with much lower expression levels 
in differentiating oligodendrocytes when compared with Glast or Glt-1, namely 
Eaac1, knock-down of gene expression was seen to only attenuate the effect of 
L-glutamate on the oligodendrocyte’s process network (siCtrl+Glu: 157±7%, 
siEaac1: 136±6%, p=0.007, ANOVA).  Taken together, these data demonstrate 
that L-glutamate can promote morphological maturation of differentiating 
oligodendrocytes via a sodium-dependent glutamate transporter-mediated 
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mechanism. In addition, they suggest that even a slight decline in 
oligodendroglial sodium-dependent glutamate transporter expression can 
significantly reduce the effect of L-glutamate on the morphological maturation of 
differentiating oligodendrocytes.  
 
Activation of sodium-dependent glutamate transporters in differentiating 
oligodendrocytes leads to a transient increase in intracellular calcium 
levels  
Having established that activation of sodium-dependent glutamate transporters 
promotes the morphological maturation of differentiating oligodendrocytes, we 
next wished to explore potential downstream signaling events involved in this 
process. These signaling-related studies were focused on calcium-mediated 
events, since it had previously been demonstrated that glutamate transport can 
activate the reverse mode of the sodium/calcium exchanger and thereby lead to 
a transient increase in intracellular calcium levels (Rojas et al., 2007, Martinez-
Lozada et al., 2011, Lopez-Colome et al., 2012). To assess the effect of an 
activation of sodium-dependent glutamate transporters on intracellular calcium 
levels, D-aspartate was used as a glutamate-equivalent agonist. Using this 
strategy, a contribution of AMPA/kainate receptor activation to the observed 
transient increase in permeability to calcium (Fig. 4.3) could be excluded. The D-
aspartate-induced transient increase in free intracellular calcium levels within 
differentiating oligodendrocytes was found to be dose-dependent (Fig. 4.3B) and 
to be absent in the presence of TBOA (Fig. 4.3C).  In addition, no such increase 
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was observed in the absence of extracellular calcium (Fig. 4.3B). Taken together, 
these data support the idea that in differentiating oligodendrocytes L-glutamate 
(as D-aspartate) activates sodium-dependent glutamate transporters which in 
turn mediate a transient increase in intracellular calcium levels via entry from the 
extracellular environment. Furthermore, it is of note that the D-aspartate-
mediated transient increase in intracellular calcium levels was observed first 
within cellular processes and then within the cell body, thus suggesting that the 
sodium-dependent glutamate transporter-evoked intracellular calcium response 
may initially occur locally within oligodendrocyte processes.  
 
The maturation promoting effect of sodium-dependent glutamate 
transporters in differentiating oligodendrocytes is mediated by a transient 
phosphorylation event within CaMKIIβ’s actin binding domain 
Our recent data provided good evidence for a critical role of the calcium sensor 
CaMKIIβ and in particular its actin binding/stabilizing domain in regulating 
oligodendrocyte maturation and myelination (Waggener et al., 2013). Thus, 
CaMKIIβ and in particular its actin binding/stabilizing domain may be directly 
involved in the sodium-dependent glutamate transporter-mediated effect 
described here. Indeed, pre-treatment of differentiating oligodendrocytes with 
KN93, a membrane-permeable pharmacological inhibitor of CaMKIIβ’s kinase 
catalytic as well as actin binding/stabilizing activity (Lin and Redmond, 2008, 
Sumi, 1991 #1025), was found to block the maturation-promoting effect of L-
glutamate on the oligodendrocyte’s process network (Fig. 4.4A). It is of note that 
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KN93 treatment alone and thus a continuous inhibition of CaMKII activity 
attenuated the morphological maturation of differentiating oligodendrocytes (Fig. 
4.4A). This effect has been previously described and was found to not be 
associated with a change in cellular viability (Waggener et al., 2013).  
To further assess the effect of L-glutamate on CaMKII and in particular 
CaMKIIβ’s actin binding/stabilizing domain in differentiating oligodendrocytes, 
phosphorylation events at CaMKII’s T287/6 and CaMKIIβ’s S371 site were analyzed. 
CaMKII’s T287/6 site represents CaMKII’s authophosphorylation site, which due to 
sequence conservation could only be detected by pan pCaMKII T287/6 antibodies.  
CaMKIIβ’s S371 site is located within CaMKIIβ’s actin binding/stabilizing domain 
(Kim et al., 2011), and antibodies specifically recognizing the pCaMKIIβ S371 site 
have been generated by us. These antibodies were found to not recognize 
CaMKIIβ S371A, a mutant form of CaMKIIβ, which cannot be phosphorylated at its 
S371 site (data not shown). As shown in Fig. 4.4B,C, treatment of differentiating 
oligodendrocytes with L-glutamate led to a significant increase in phosphorylation 
at CaMKIIβ's S371 site. This effect was time-dependent and transient, since an 
increase in phosphorylation was not seen prior to 30 min of treatment and at 4 
hours and beyond (Fig. 4.4C,F). Furthermore, no such increase in 
phosphorylation was observed at CaMKII’s autophosphorylation (T286/7) site 
within 15-60 min of L-glutamate treatment (Fig. 4.4E), nor was a change in total 
levels of CaMKIIβ noted (Fig. 4.4D). Importantly, the effect of L-glutamate on the 
phosphorylation at CaMKIIβ's S371 site could be blocked by pre-treatment with 
TBOA (Fig. 4.4G), thus demonstrating that activation of sodium-dependent 
 
 
 
 
 
88 
glutamate transporters mediates a phosphorylation event within CaMKIIβ's actin 
binding/stabilizing domain. To further assess the contribution of individual 
sodium-dependent glutamate transporter genes in this L-glutamate-mediated 
increase in pCaMKIIβ S371 levels, differentiating oligodendrocytes were 
transfected with siRNA pools specifically targeting Glast, Glt-1 or Eaac1 
expression. Similar to what was observed for the effect of gene-specific knock-
down of sodium-dependent glutamate transporter expression on the 
oligodendrocyte’s network area (Fig. 4.2F), knock-down of Glast or Glt-1 
expression eliminated the effect of L-glutamate on the phosphorylation of 
CaMKIIβ's S371 site,  while the effect of a knock-down of Eaac1 expression 
appeared less pronounced.  
 
Phosphorylation events within CaMKIIβ’s actin binding domain appear to 
regulate the association of CaMKIIβ with filamentous F-actin and the effect 
of glutamate on the oligodendrocyte’s process network 
Our data described so far demonstrated that in differentiating oligodendrocytes, 
L-glutamate activates sodium-dependent glutamate transporters, which in turn 
mediate a transient increase in intracellular calcium levels, a transient 
phosphorylation event at CaMKIIβ’s S371 site and a promotion of the 
morphological aspects of oligodendrocyte maturation. In addition, our recent data 
demonstrated that upon increases in intracellular calcium levels, serine, including 
S371, and threonine residues are phosphorylated within CaMKIIβ’s actin binding 
domain, and that these phosphorylation events are sufficient to induce 
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detachment of CaMKIIβ from filamentous F-actin (Kim et al., 2011). Taken 
together, the above findings raised the possibility that sodium-dependent 
glutamate transporter-mediated phosphorylation within CaMKIIβ’s actin 
binding/stabilizing domain may affect the oligodendrocyte’s process network via 
a change in CaMKIIβ’s association with filamentous F-actin. To investigate this 
idea, mutant forms of eGFP fusion proteins of CaMKIIβ were generated that 
either represented CaMKIIβ in which the serine and threonine residues within in 
the actin binding/stabilizing domain are non-phosphorylatable (eGFP-
CaMKIIβallA) or their phosphorylated state is mimicked (eGFP-CaMKIIβallD). In 
addition, eGFP-CaMKIIβWT and eGFP-CaMKIIβK43R, a mutant that is impaired in 
ATP binding and thus inactive with regard to its kinase catalytic but not actin 
binding activity (Okamoto et al., 2007), were used. Consistent with the previously 
characterized role of phosphorylation events within CaMKIIβ’s actin 
binding/stabilizing domain on CaMKIIβ’s association with filamentous F-actin, 
nucelofection studies using plasmids encoding the above described eGFP-
CaMKIIβ forms revealed individual subcellular distribution patterns (Fig. 4.5A,B). 
More specifically, in cells of the oligodendroglial cell line CIMO, the non-
phosphorylatable eGFP-CaMKIIβallA form was found to largely co-localize with 
filamentous F-actin (Fig. 4.5A). Similarly, it was detected in differentiating 
oligodendrocytes at subcellular locations at which filamentous F-actin has been 
previously described to be enriched (Fig. 4.5B), namely within oligodendrocyte 
growth cones and at process branching points (Song et al., 2001, Fox et al., 
2006a). In contrast, the phospho-mimetic eGFP-CaMKIIβallD form showed little 
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co-localization with filamentous F-actin and appeared similar to eGFP distributed 
diffusely and throughout the cytoplasm (Fig. 4.5A,B). In agreement with a likely 
only partially phosphorylated state, eGFP-CaMKIIβWT displayed a somewhat 
intermediate subcellular distribution (Fig. 4.5A,B). It is of further note that the 
eGFP tag used here has been previously shown to not interfere with CaMKIIβ 
function (Okamoto et al., 2004, Okamoto et al., 2007).  
To correlate the phosphorylation state of CaMKIIβ’s actin binding/stabilizing 
domain und thus its level of association with filamentous F-actin with the 
morphological maturation of differentiating oligodendrocytes, the effect of the 
expression of the different eGFP-CaMKIIβ forms on the oligodendrocyte’s 
process network was evaluated. As shown in Fig. 4.5C, expression of the non-
phosphorylatable eGFP-CaMKIIβallA form blocked the maturation-promoting 
effect of L-glutamate treatment. No such effect was observed when eGFP-
CaMKIIβWT or eGFP-CaMKIIβK43R were expressed, suggesting that the L-
glutamate-mediated maturation-promoting effect may not require CaMKIIβ’s 
kinase catalytic activity. Importantly and consistent with our previous findings 
(Waggener et al., 2013); Fig. 4.4A), constitutive expression of the phospho-
mimetic eGFP-CaMKIIβallD form attenuated the morphological maturation of 
differentiating oligodendrocytes and eliminated the effect of L-glutamate 
treatment on the cell’s process network. Taken together, these data support the 
idea that phosphorylation within CaMKIIβ’s actin binding/stabilizing domain 
leading to detachment of CaMKIIβ from filamentous F-actin, is a required step in 
the mechanism promoting the morphological aspects of oligodendrocyte 
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maturation via activation of sodium-dependent glutamate transporters. Notably, 
constitutive (vs. transient) phosphorylation within CaMKIIβ’s actin 
binding/stabilizing domain appears to have an opposing effect.  
 
DISCUSSION 
The study described here, investigated the role of sodium-dependent glutamate 
transporters in the regulation of oligodendrocyte differentiation. Our data 
demonstrated that activation of in particular GLAST and GLT-1 in differentiating 
oligodendrocytes promotes their morphological maturation. On a molecular level, 
this sodium-dependent glutamate transporter-mediated promotion of 
oligodendrocyte maturation was found to be associated with transient increases 
in intracellular calcium levels (from the extracellular environment) and 
phosphorylation at CaMKIIβ’s S371 site located within CaMKIIβ’s actin 
binding/stabilizing domain. In addition, our data revealed a requirement for 
phosphorylation events within CaMKIIβ’s actin binding/stabilizing domain. These 
phosphorylation events appeared furthermore to regulate CaMKIIβ’s association 
with filamentous F-actin. Based on these data and the ascribed function of 
CaMKIIβ’s actin binding/stabilizing domain in the regulation of dendritic spine 
morphology (Okamoto et al., 2009), we propose the following model for the role 
of sodium-dependent glutamate transporters in the regulation of oligodendrocyte 
maturation (Fig. 4.6). Under basal conditions, CaMKIIβ is in differentiating 
oligodendrocytes to a large extent associated with the actin cytoskeleton. 
Glutamate release from for example un-myelinated axonal segments activates 
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oligodendroglial sodium-dependent glutamate transporters, which in turn activate 
the reverse mode of oligodendroglial sodium/calcium exchangers resulting in a 
transient increase in intracellular calcium levels (Fig. 4.6A). This increase in 
intracellular calcium levels leads to phosphorylation events within CaMKIIβ’s 
actin binding/stabilizing domain (including CaMKIIβ’s S371 site), inactivation of 
CaMKIIβ's actin binding activity and detachment of CaMKIIβ from the actin 
cytoskeleton. Such transient inactivation of CaMKIIβ's actin binding activity 
opens a time window during which actin cytoskeleton remodeling events and 
actin polymerization (Okamoto et al., 2007, Sanabria et al., 2009, Hoffman et al., 
2013) are favored (Fig. 4.6B). This dynamic phase is then followed by a phase of 
actin cytoskeleton stabilization via re-activation of CaMKIIβ's actin binding activity 
via de-phosphorylation (Fig. 4.6C). It is of note that the actin binding activity of 
CaMKIIβ appears to be independent of its kinase catalytic activity, a concept that 
is supported by recent in vivo studies (van Woerden et al., 2009, Borgesius et al., 
2011). Also, actin binding properties have been described for other members of 
the CaMKII gene family, even though via a different structure-function domain 
(Caran et al., 2001, Hoffman et al., 2013). Further studies will be necessary to 
evaluate a potential contribution of CaMKII isozymes other than CaMKIIβ in the 
molecular mechanism described here. Importantly, constitutive inactivation of 
CaMKIIβ's actin binding activity, in contrast to transient inactivation, appears to 
attenuate the morphological maturation of differentiating oligodendrocytes, an 
effect that is likely mediated by de-stabilization of the actin cytoskeleton over an 
extended period of time (Waggener et al., 2013). Thus, it is cycles of activation 
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and de-activation of CaMKIIβ’s actin binding activity that allow re-organization of 
the actin cytoskeleton and a promotion of the morphological aspects of 
oligodendrocyte maturation. This idea is further supported by recent findings 
demonstrating that balanced activation and de-activation of the actin filament 
severing and depolymerizing factor cofilin regulates the function of the 
myelinating cells of the peripheral nervous system, namely Schwann cells 
(Sparrow et al., 2012).  
Our studies revealed a prominent expression of the sodium-dependent 
glutamate transporter gene Glast in differentiating oligodendrocytes. This finding 
is in agreement with previous observations made in tissue culture as well as in 
vivo in both rodents and humans (Domercq and Matute, 1999, Pitt et al., 2003, 
Vallejo-Illarramendi et al., 2006, Regan et al., 2007, DeSilva et al., 2009). In 
addition, a low level expression of Eaac1 is consistent with the reported presence 
of few Eaac1-positive cells in the developing optic nerve (Domercq and Matute, 
1999). In contrast, the expression of Glt-1 in cells of the oligodendrocyte lineage 
appears more complicated, since it has in particular in vivo been described to be 
developmentally regulated and to be predominant at stages at which 
oligodendrocytes are premyelinating (Domercq and Matute, 1999, Desilva et al., 
2007, DeSilva et al., 2009). Our previous data revealed a prominent in vivo role 
of CaMKIIβ in the regulation of myelin thickness (Waggener et al., 2013) and 
thus likely not only in premyelinating but also myelinating oligodendrocytes. 
Thus, a developmentally regulated expression pattern of Glt-1 as described 
above would suggests that the signaling pathway proposed here (Fig. 4.6) may in 
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vivo be primarily mediated by GLAST and less so by GLT-1. However, in human 
tissue the expression of Glt-1 has been reported to occur in mature 
oligodendrocytes (Werner et al., 2001, Pitt et al., 2003). Thus, additional studies 
will be necessary to more precisely define individual sodium-dependent 
glutamate transporter contributions and potential species-specific differences. It 
is of further note that while development in mice with single knock-outs for Glast, 
Glt-1 or Eaac1 occurs without apparent CNS gross phenotypes (Peghini et al., 
1997, Tanaka et al., 1997, Harada et al., 1998), double Glast/Glt-1 knockout 
mice die in utero and show multiple developmental brain defects (Matsugami et 
al., 2006). These data indicate that during CNS development the loss of one 
sodium-dependent glutamate transporter may functionally be compensated for by 
at least one of the remaining transporters, i.e. by a mechanism that could further 
complicate a delineation of individual roles for individual sodium-dependent 
glutamate transporters.  
Our model proposed in Fig. 4.6 is suggestive of pivotal roles for 
oligodendroglial sodium/calcium exchangers and intracellular calcium levels in 
the regulation of oligodendrocyte maturation. It is thus noteworthy that the 
sodium/calcium exchanger NCX3 has recently been implicated in the regulation 
of oligodendrocyte differentiation (Boscia et al., 2012a). In addition, process 
outgrowth has been found to be regulated by intracellular calcium levels in 
differentiating oligodendrocytes (Yoo et al., 1999). Interestingly, in our studies 
(Fig. 4.3) intracellular calcium levels remained slightly above control levels after 
the initial rise. Such a calcium response is consistent with previously described 
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calcium responses mediated by signaling through sodium-dependent glutamate 
transporters in astrocytes (Rojas et al., 2007). In the case of astrocytes the initial 
rise in intracellular calcium concentrations was found to be amplified by calcium 
release from ryanodine sensitive calcium stores (Rojas et al., 2007), which have 
also been described to be expressed by cells of oligodendrocyte lineage 
(Simpson et al., 1998).  
In the major demyelinating disease in human, Multiple Sclerosis (MS), a block 
in oligodendrocyte differentiation is considered one of the main causes of 
remyelination failure and repair under such pathological conditions (Chang et al., 
2002, Fancy et al., 2010, Kremer et al., 2011). Interestingly, reduced sodium-
dependent glutamate transporter protein levels have been reported for white 
matter areas surrounding MS lesions (Werner et al., 2001, Pitt et al., 2003). In 
addition, retrospective analysis of brain tissue from MS patients revealed 
oligodendrocyte differentiation block as the major determinant of remyelination 
failure within periplaque white matter regions (Kuhlmann et al., 2008). In light of 
our findings that knock-down of sodium-dependent glutamate transporter 
expression eliminates the effect of glutamate on the morphological maturation of 
differentiating oligodendrocytes (Fig. 4.2F), it is tempting to speculate that 
changes in sodium-dependent glutamate transporter expression may contribute 
to the differentiation block seen in MS. It is of further note that glutamate levels 
have been found elevated in MS brains (Werner et al., 2001, Srinivasan et al., 
2005, Trapp and Stys, 2009). These changes in glutamate homeostasis have 
been implicated in mediating excitotoxicity (Pitt et al., 2003, Matute, 2011). 
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However, human oligodendrocytes appear to be largely resistant to such 
glutamate-mediated injury (Wosik et al., 2004) and thus changes in glutamate 
homeostasis and sodium-dependent glutamate transporter expression may, at 
least under certain circumstances, primarily limit repair under pathological 
conditions as they are seen in the CNS of MS patients.  
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FIGURE 4.1: Sodium-dependent glutamate transporters are expressed in 
differentiating oligodendrocytes. A: Bar graph representing sodium-dependent 
glutamate transporter mRNA levels as determined by qRT-PCR analysis. Total 
glutamate transporter mRNA levels (Glast+Glt-1+Eaac1) were set to 100% and 
the values for the individual gene-specific mRNA levels were adjusted 
accordingly. Data represent means ± SEM (n = 3 independent experiments, 
***p≤0.001, ANOVA). B: Sodium-dependent glutamate transporter protein levels 
as determined by immunoblot analysis. Representative blots are shown. The 
numbers to the left indicate molecular weights in kDa.  
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FIGURE 4.2: The activation of sodium-dependent glutamate transporters 
promotes the morphological aspects of oligodendrocyte differentiation. A: 
Representative images of differentiating oligodendrocytes immunostained using 
O4 hybridoma supernatants and treated as indicated: control (Ctrl), L-glutamate 
(Glu; 100 µM), a non-transportable inhibitor of sodium-dependent glutamate 
transport (TBOA; 100 µM). Scale bars: 20 µm. B-D: Bar graphs representing 
quantitative analyses of network areas (Dennis et al., 2008). Cells were treated 
as indicated: control (Ctrl), L-glutamate (Glu, 100 µM), a non-transportable 
inhibitor of sodium-dependent glutamate transport (TBOA, 100 µM), D-aspartate 
(Asp, 100 µM). The mean values for control (non-treated) cells were set to 100% 
and experimental values were calculated accordingly. At least 30 cells per 
condition and experiment were analyzed in 3 independent experiments (i.e. a 
total of at least 90 cells per condition). Data represent means ± SEM (***p≤0.001 
compared to control, ANOVA).  E: Bar graph depicting the number of MBP-
immuno-positive cells normalized to the number of Hoechst-positive nuclei. The 
inset shows a representative image of cells cultured under control (non-treated) 
conditions and stained with an antibody specific for MBP (left panel) as well as 
with Hoechst to visualize nuclei (right panel). Cells were treated as indicated and 
control (non-treated) values were set to 100%. Experimental values were 
calculated accordingly. Data represent means ± SEM of 3 independent 
experiments in which a field of view of 508 µm2 per coverslip and 3 coverslips per 
condition and experiment were analyzed. Three independent experiments were 
performed. ANOVA revealed no statistically significant difference (p≤0.05). F: Bar 
graph depicting the network area upon siRNA-mediated knock-down of individual 
sodium-dependent glutamate transporters (as indicated) and subsequent 
treatment with L-glutamate (Glu, 100 µM). The mean value for control cells (siCtrl 
non-treated) was set to 100%. Experimental values were calculated accordingly. 
At least 30 cells per condition and experiment were analyzed in 3 independent 
experiments (i.e. a total of at least 90 cells per condition). Data represent means 
± SEM (***p≤0.001 compared to siCtrl non-treated, ANOVA).  
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FIGURE 4.3: The activation of sodium-dependent glutamate transporters 
increases intracellular calcium levels in differentiating oligodendrocytes. A: 
Representative pseudo-colored images of fura-2 AM ratio fluorescence 
measurements made in differentiating oligodendrocytes and upon treatment with 
D-aspartate (Asp). The bar to the left represents a relative color scale indicating 
low (L) and high (H) calcium levels. B-C: Time course of changes in free 
intracellular calcium concentrations [Ca2+] as detected by fura-2 AM ratiometric 
measurements made in differentiating oligodendrocytes and upon different 
treatments as indicated in the inset shown in the upper right in B and C. Start of 
treatment is indicated by the arrow. The graphs represent means ± SEM of 
measurements taken from 9 cells per treatment group and experiment and from 
3 independent experiments (i.e. a total of 27 cells per treatment group).  
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FIGURE 4.4: Activation of sodium-dependent glutamate transporters leads to a 
transient phosphorylation event at CaMKIIβ’s S371 residue. A: Bar graph 
depicting a quantitative analysis of the oligodendrocyte’s network area (Dennis et 
al., 2008). Cells were first pre-treated with the pharmacological CaMKII inhibitor 
KN-93 or its inactive derivative KN-92 as control and then incubated in the 
absence or presence (+Glu) of 100 µM L-glutamate. The mean values for control 
cells (pre-treated with KN92 and incubated in the absence of L-glutamate) were 
set to 100% and experimental values were calculated accordingly. At least 30 
cells per condition and experiment were analyzed in 3 independent experiments 
(i.e. a total of at least 90 cells per condition). Data represent means ± SEM 
(***p≤0.001 compared to control, ANOVA). The inset (upper right) depicts 
representative images of differentiating oligodendrocytes immunostained with O4 
antibodies and treated with KN-92 plus L-glutamate (left) or KN-93 plus L-
glutamate (right). Scale bars: 5µm. B, inset in H: Representative Western blots 
depicting CaMKII phosphorylation (pCaMKIIβ S371, pCaMKII T286/7) or total 
CaMKIIβ protein levels. GAPDH protein levels are shown representatively for the 
Western blot for which anti- pCaMKII T286/7 (B) or anti-pCaMKIIβ S371 (inset in H) 
antibodies were used. C-H: Bar graphs depicting the levels of pCaMKIIβ S371 
(C,F-H), total CaMKIIβ (D) or pCaMKII T286/7 (E) at different time-points after 
addition of L-glutamate (Glu) (C-F), at time-point 60 min after addition of L-
glutamate and prior pre-treatment with or without TBOA (G) or after transfection 
with siRNA pools as indicated and L-glutamate treatment for 60 min (H). Levels 
of phosphorylated or total CaMKII protein were normalized to GAPDH protein 
levels. The mean normalized values for control (non-treated) cells were set to 
100% (horizontal line) and experimental values were calculated accordingly. 
Data represent means ± SEM of 3 independent experiments (*p≤0.01 compared 
to control, ANOVA).  
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FIGURE 4.5: Phosphorylation events within CaMKIIβ’s actin binding/stabilizing 
domain regulate the association of CaMKIIβ with filamentous F-actin and the 
glutamate-mediated promotion of the morphological aspects of oligodendrocyte 
maturation. A: Representative images of cells of the oligodendroglial cell line 
CIMO nucleofected with plasmids encoding eGFP fusion proteins of CaMKIIβ 
(WT and mutant forms as indicated) and stained for F-actin (phalloidin). Scale 
bars: 5 µm.  B: Representative images of differentiating oligodendrocytes 
nucleofected with plasmids encoding eGFP fusion proteins of CaMKIIβ (WT and 
mutant forms as indicated). Arrowheads point toward eGFP-CaMKIIβallA localized 
at oligodendrocyte growth cones and process branching points. Scale bars: 5 
mm. C: Bar graph depicting a quantitative analysis of the oligodendrocyte’s 
network area (Dennis et al., 2008). Cells were nucleofected as indicated and 
then incubated in the absence or presence (+Glu) of 100 µM L-glutamate. The 
mean values for control cells (nucleofected with a eGFP encoding plasmid and 
incubated in the absence of L-glutamate) were set to 100% and experimental 
values were calculated accordingly. At least 30 cells per condition and 
experiment were analyzed in 3 independent experiments (i.e. a total of at least 
90 cells per condition). Data represent means ± SEM (***p≤0.001 compared to 
control, ANOVA). 
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FIGURE 4.6: Proposed model for a glutamate transporter-CaMKIIβ-actin 
cytoskeleton axis in the regulation of oligodendrocyte maturation. A: L-glutamate 
(Glu) stimulates the activity of sodium-dependent glutamate transporter activity, 
which in turn leads to an increase in intracellular sodium (Na+) levels, activation 
of the reverse mode of the sodium/calcium exchanger and a transient increase in 
intracellular calcium (Ca2+) levels. B: The transient increase in intracellular 
calcium levels leads to phosphorylation events within CaMKIIβ’s actin 
binding/stabilizing domain (pCaMKIIβS371), detachment of CaMKIIβ from 
filamentous F-actin and the opening of a time window during which cytoskeletal 
rearrangements and morphological remodeling can occur. C: Upon deactivation 
(dephosphorylation) of CaMKIIβ, CaMKIIβ binds to filamentous F-actin and 
thereby stabilizes the newly arranged cytoskeleton. Such cycles of activation and 
de-activation of CaMKIIβ’s actin binding activity allow re-organization of the actin 
cytoskeleton while at the same time preventing its uncontrolled disintegration. 
adapted from Okamoto et al, 2009(Okamoto et al., 2009).  
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FIGURE 4.S1: siRNA-mediated gene silencing results in a significant knock-
down of sodium-dependent glutamate transporter expression in differentiating 
oligodendrocytes. A: Bar graph depicting sodium-dependent glutamate 
transporter protein levels upon siRNA-mediated gene silencing and normalized to 
GAPDH protein levels. The mean value for cells treated with the control siRNA 
pool (siCtrl) was set to 100% (horizontal gray line) and experimental values were 
calculated accordingly. Data represent means ± SEM of 3 independent 
experiments (***p≤0.001,*p≤0.05, ANOVA). B: Representative Western blots 
depicting protein levels for GLAST, GLT-1, EAAC1 and GAPDH (as control). 
GAPDH protein levels are shown representatively for the Western blot, for which 
anti-EAAC1 antibodies were used. 
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CHAPTER 5 
Final Conclusions 
 
The myelin sheath that is produced by oligodendrocytes in the CNS serves a 
unique and critical function for proper conduction of nerve signals. Disruption of 
the myelin sheath leads to improper nerve conduction resulting in unpredictable 
debilitating afflictions for people as seen in the most well known demyelinating 
disease MS. As mentioned in Chapter 1, in the MS brain there are 
oligodendrocytes present within CNS-located lesions, however, they lack the 
ability to efficiently remyelinate (Chang et al., 2002). When remyelination does 
occur, the myelin sheath is thinner and is too inefficient to provide proper axonal 
protection and propagation of the electrical signal (Patrikios et al., 2006, 
Goldschmidt et al., 2009, Bradl and Lassmann, 2010, Emery, 2010). A better 
understanding of the molecular mechanisms that regulate oligodendrocyte 
maturation and development is thought to provide molecular and genetic clues to 
better understand not only developmental myelination but also how to promote 
remyelination under pathological conditions. 
Unlocking the molecular secrets to myelination may enlighten researchers to 
a complex understanding of the morphological maturation of the oligodendrocyte. 
Morphological maturation along with gene regulation can go hand in hand or be 
separate, and to an extent one can drive the one or the other (Boggs, 2006, 
Boggs et al., 2006, Forrest et al., 2009, Lafrenaye and Fuss, 2010). Myelination 
requires the maturation of progenitor cells into cells that extend processes and 
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form a complex process network. These premyelinating oligodendrocytes then 
transition into mature myelinating oligodendrocytes (Song et al., 2001, Bacon et 
al., 2007, Bauer et al., 2009).  These large scale morphological changes are 
mediated by precisely regulated changes in the actin cytoskeleton (Bauer et al., 
2009). This fine actin regulation is highlighted by myelin defects seen in 
knockouts or knockdowns of cytoskeletal regulatory proteins such as WAVE1, 
cdc42, RAC1, Integrin-linked kinase (ILK), and Mayven (Jiang et al., 2005, Kim et 
al., 2006, Thurnherr et al., 2006, O'Meara et al., 2013). Interestingly, in MS 
lesions proteomic studies have revealed a large amount of misregulated 
cytoskeletal regulatory mechanisms (Jahn et al., 2009, Satoh et al., 2009).  
As stated above, changes in oligodendrocyte development usually are 
characterized by large scale changes of the oligodendrocyte process network 
and the underlying actin cytoskeleton. In Chapter 2, by using in vitro tissue 
culture as well as in vivo knockout and knock-in models, CaMKIIβ has been 
shown to be a critical component of the molecular mechanisms regulating 
oligodendrocyte maturation and CNS myelination. CaMKIIβ’s properties in 
binding and stabilizing actin have been established in neuronal spine morphology 
but our finding of CaMKIIβ’s role in the regulation of oligodendrocyte 
development and the formation of a complex process network is novel. (Shen et 
al., 1998, O'Leary et al., 2006, Okamoto et al., 2007, Lin and Redmond, 2008, 
Okamoto et al., 2009, Sanabria et al., 2009).  
In neurons and oligodendrocytes, the stabilization along with the 
destabilization of the actin cytoskeleton causes the fluidity of process elongation 
 
 
 
 
 
113 
along with membrane spreading (Bradke and Dotti, 1999, Okamoto et al., 2007, 
Okamoto et al., 2009). Furthermore, in neurons, the bundling and unbundling of 
actin acts to alter and stabilize the morphology of dendritic spines based on 
activity dependent plasticity (Okamoto et al., 2009). Evidence presented in 
Chapter 2 points towards the binding of actin to CaMKIIβ using colocalization 
studies.  The evidence also suggests that once CaMKIIβ’s catalytic activity and 
actin binding is inhibited with a pharmacological inhibitor, there is no indication of 
colocalization (Chapter 2). Actin colocalization with CaMKIIβ suggests that the 
model of CaMKIIβ binding and dissociating from actin allows stabilization and 
alteration of the cytoskeleton respectively.  Although this was developed for 
remodeling of the dendritic spine, it could also apply to the remodeling of 
oligodendrocyte protrusions. Based on previous data, one could assume that 
process outgrowth and maintenance of the process cytoskeleton is dependent on 
the balanced destabilization (unbinding) and stabilization (binding) of the actin 
cytoskeleton to a bundling molecule such as CaMKIIβ for controlled process 
outgrowth and myelination (Bradke and Dotti, 1999, Sparrow et al., 2012). 
Similarly, the activation and then deactivation of cofilin (the actin filament 
severing and depolymerizing factor) regulates Schwann cell myelination 
(Sparrow et al., 2012). This provides further support that well-balanced and 
controlled cytoskeletal reorganization and fluidity are critical for proper 
myelination.  
In the CaMKIIβ knockout mice, differences in myelin thickness in the ventral 
spinal cord were noticed in young and adult mice indicating that CaMKIIβ is 
 
 
 
 
 
114 
critical for proper myelination of the CNS. A similar phenotype has been seen in 
in conditional (oligodendrocyte specific) ERK1/ERK2 double knockout mice. 
Thinner myelin was seen with no changes in the numbers of oligodendrocytes; 
however, there were some changes seen in the expression of myelin genes (Ishii 
et al., 2012). The resulting similar phenotype seen between CaMKIIβ knockouts 
and ERK1/ERK2 double knockouts could potentially be attributed to overlapping 
signaling mechanisms.   Once upstream signals (ERK1/ERK2 or CaMKIIβ) are 
knocked out, similar phenotypes arise. Conversely, these two signaling pathways 
could be different but provide a similar function since myelination is critical for 
normal development of the CNS. If we assume that CaMKIIβ is binding to actin 
and regulates actin binding and unbinding during the unbound state, it could 
potentially modulate ERK1/2 signaling as it has been described to do in other cell 
types (Lu et al., 2005). Additionally, ERK1/2 signaling in other cell types is linked 
to signaling that regulates actin polymerization and substrate detachment of the 
actin cytoskeleton when ERK1/2 signals to myosin light chain kinase or Calpain 
respectively (Katz et al., 2007). Therefore signaling mechanisms that regulate 
ERK1/2 dependent myelination could potently overlap with signaling related to 
CaMKIIβ dependent myelination.  Changes in gene expression cannot be 
compared specifically between ERK1/2 knockouts and CaMKIIβ knockouts 
because gene expression has not been carefully assessed in the latter. However, 
by comparing studies done in vitro by knocking down CaMKIIβ with studies that 
knocked out ERK1/2, it could be assumed that these signaling mechanisms 
could be different but provide a similar outcome. In this proposed outcome, 
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ERK1/2 is regulating the genetic component of oligodendrocyte development and 
CaMKIIβ is regulating the morphological maturation component of 
oligodendrocyte development (Ishii et al., 2012, Waggener et al., 2013). Thus, 
two different developmental pathways are impacted but the same improper 
regulation of myelination could potentially be observed. 
 
Glutamate activates CaMKIIβ and increases the overall morphology of the 
oligodendrocyte’s process network  
As mentioned in Chapter 3, glutamate signaling in the brain is critical for 
normal brain development. Furthermore, as the nervous system develops and 
oligodendrocyte processes are looking to attach to axons, glutamate is being 
released in a vesicular fashion from unmyelinated axons (Kukley et al., 2007, 
Ziskin et al., 2007, Hamilton et al., 2010). The data presented in Chapter 4 
suggest that maturing oligodendrocytes may respond to axonal released 
glutamate which would stimulate myelination.  
In Chapter 4, the data demonstrated that sodium-dependent glutamate 
transporters are important for the regulation of oligodendrocyte differentiation. 
More specifically, the data showed that activation of sodium-dependent 
glutamate transporters promotes oligodendrocyte morphological maturation via 
transient increases in intracellular calcium and phosphorylation of CaMKIIβ’s S371 
site found within CaMKIIβ’s actin binding/stabilization domain. These 
phosphorylation events seem to mediate CaMKIIβ’s association with F-actin and 
give further insight into the role that CaMKIIβ potentially plays during actin 
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binding and stabilization of the oligodendrocyte process network. These data 
show that there is a functional relationship between glutamate transporters and 
oligodendrocyte development. It has been shown that electrical activity via axons 
regulates myelination (Malone et al., 2013). More specifically, the glutamate 
released from electrically active unmyelinated axons has been implicated in 
increased development and then subsequent myelination of oligodendrocyte 
progenitor cells (Kukley et al., 2007, Ziskin et al., 2007, Bakiri et al., 2009, 
Kolodziejczyk et al., 2010).  
Altering the binding properties of the serine/threonine residues within the 
actin binding domain changes the way CaMKIIβ binds to actin. This 
phosphorylation-dependent binding of actin is a novel finding and our data 
suggests the regulatory mechanisms mediated by CaMKIIβ’s actin binding site in 
oligodendrocytes are comparable to ones proposed in neurons and in particular 
in dendritic spines (Okamoto et al., 2009).  These data are the first evidence that 
oligodendrocytes use CaMKIIβ to bind to actin and that the phosphorylation of 
serine/threonine residues within the actin binding site regulate the arrangement 
and organization of the oligodendrocyte actin cytoskeleton.  
If CaMKIIβ is critical for proper myelination, then alterations may be seen 
in diseases such as MS that have oligodendrocytes with simple process 
morphologies and limited/insufficient myelination. In some MS lesions, there 
seems to be an upregulation at the S371 site of CaMKIIβ (our own unpublished 
data). 
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Interestingly, the signaling mechanisms that potentially govern 
oligodendrocyte process guidance towards the axon may indeed be altered in 
MS. Higher levels of glutamate have been shown in normal appearing white 
matter and lesioned areas of MS brains (Werner et al., 2001, Trapp and Stys, 
2009, Tisell et al., 2013). However, lower levels of glutamate transporter 
expression have also been reported for MS lesions (Werner et al., 2001, Pitt et 
al., 2003). Since our data show that glutamate stimulates the phosphorylation of 
the actin biding domain of CaMKIIβ and causes it to dissociate from F-actin, 
physiological higher concentrations of glutamate or more glutamate/Ca2+ being 
transported could cause destabilization of the actin cytoskeleton. This effect 
would be similar to the CaMKIIβAllD (always actin unbound) mutant, expression of 
which results in a significant decrease in the process network of 
oligodendrocytes. If the environment around these immature oligodendrocytes is 
altered (higher glutamate concentrations), then constant destabilization of the 
actin cytoskeleton could lead to process retraction or process collapsing (Meng 
et al., 2010, Nagel et al., 2012). It is critical that the periods of actin 
destabilization be followed up with periods of actin stabilization to achieve a 
proper balance of actin dynamics (Sparrow et al., 2012).  
Downstream activation of the reverse mode of NCX3 (sodium calcium 
exchanger) is one way to restore the Na+ equilibrium after glutamate transport. 
As previously discussed, the restoration of Na+ efflux allows for Ca2+ influx, at 
least in Bergmann glia cells (Martinez-Lozada et al., 2011). The subcellular 
location of NCX3 was described to be within the process network of MOG 
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positive cells in culture and also within compacted myelin in MBP positive cross 
sections of axons in spinal cord white matter (Boscia et al., 2012b). It has been 
theorized and speculated but poorly understood for years that there are signals 
that are exchanged between the axon and the myelin sheath to communicate the 
regulation of thickness and maintenance of the myelin sheath (Nave and Trapp, 
2008, Nave, 2010).  This has been well demonstrated for the PNS but based on 
current research, the signals that control these events are more complex in the 
CNS (Nave and Salzer, 2006, Brinkmann et al., 2008, Taveggia et al., 2008). The 
CNS most likely requires additional uncharacterized signals to govern the 
regulation of myelin thickness. The mechanisms of glutamate signaling in 
oligodendrocytes regulating the cytoskeleton via CaMKIIβ could provide insight 
into this area of uncertainty.  
This dissertation focuses on the role that CaMKIIβ plays on oligodendrocyte 
process network formation and myelination with regards to an association of 
CaMKIIβ with the actin cytoskeleton. What has not been mentioned or 
investigated is the multifunctional kinase role that CaMKIIβ or any of the 
expressed Camk2 genes can play in oligodendrocyte development. The neuronal 
model proposes that a catalytically active CaMKIIβ disassociates from actin and 
performs its traditional and well known role as a multifunctional kinase (Okamoto 
et al., 2007, Lin and Redmond, 2009, Lakhanpal et al., 2011). In relation to 
CaMKIIβ’s kinase role, it has been shown that CaMKIIβ is a regulator of LIMK1 
by phosphorylation of LIMK1 Thr-508 site, which is then responsible for 
phosphorylation of the actin severing/depolymerizing factor cofilin (Saito et al., 
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2013). LIMK1 has been implicated in Schwann cells to activate cofilin and to thus 
be essential for PNS myelination (Sparrow et al., 2012). During the active 
unbound state of CaMKIIβ, the phosphorylative effects of the kinase could be 
acting to aid in activating actin regulatory proteins such as cofilin via LIMK1.  
The data presented in this dissertation give new insights into new molecular 
players responsible for morphological changes in the oligodendrocyte process 
network. A greater understanding of the molecular mechanisms that underlie 
process maturation could provide key clues and potential therapeutic targets for 
treating and repairing MS lesions. Oligodendrocyte progenitor cells that are found 
in the lesions of MS patients fight a host of mechanisms that keep them from the 
proper remyelination for which they are intrinsically designed. Researchers in the 
field still question whether immature oligodendrocytes in MS lesions have the 
ability to remyelinate. One of the current theories on this topic is that the addition 
of a new population of stem cells in the lesion could increase the ability of these 
new stem cells to remyelinate (Lindvall and Kokaia, 2006, Zawadzka et al., 
2010). The second theory in the field is that the cells are intrinsically normal but 
the local environment is unable to support remyelination (Ruckh et al., 2012, 
Stoffels et al., 2013). In recent studies, it was shown that when adding a younger 
environment via new young macrophages and blood derived factors, the 
inhibitory environment was rejuvenated and allowed for proper remyelination of 
older oligodendrocyte progenitor cells (Ruckh et al., 2012). One of the reasons 
that remyelination could be occurring is that macrophages which are not normally 
expressed in the CNS can take up glutamate via the EAAT transporter system 
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(Rimaniol et al., 2000).  This removal of higher levels of glutamate from the 
surrounding cells could restore the proper influx of glutamate, which would 
restore the balance of Ca2+ influx into the cells. This reduction or controlled 
elevation in Ca2+ levels would allow CaMKIIβ to normally move from an actin 
bound and unbound state with restored balance of destabilization to stabilization 
of actin.  
This dissertation and the research presented here gives overwhelming 
support for the role that CaMKIIβ plays in the regulation of actin with regards to 
oligodendrocyte process morphology and myelination. Unveiling novel signaling 
mechanisms into the complex and poorly understood field of myelination pushes 
researchers closer to a better understanding of this principle. These findings are 
of great significance because there are no current therapies available for MS 
patients today that address the issue of remyelination. This research and other 
research into oligodendrocyte development are leading to a better understanding 
of the molecular mechanisms that promote oligodendrocyte differentiation during 
development that have the potential to reveal novel targets for designing 
remyelinating therapies.  
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CHAPTER 6 
Supplementary Unpublished Data and Protocols 
 
 
CaMKII Activity In Oligodendrocytes 
 
CaMKII activity was measured in primary cells from P4 rat pups that were 
imunopanned with O4. Once immunopanned cells were either process right away 
or plated on glass coverslips coated with .1ug/ul of fibronectin and then 
harvested after a day. Cells were collected and rinsed centrifugally (2000×g for 
5 min) with ice-cold PBS (phosphate-buffered saline) containing 2.5 mM 
EGTA. Cellular pellets were resuspended in 3 volumes of ice-cold 
homogenization buffer, which consisted of 20 mM Hepes (pH 7.4), 2.6 mM 
EGTA, 20 mM MgCl2, 80 mM β-glycerol phosphate, 5 mM NaF, 0.1 µM 
okadaic acid (GIBCO-BRL), 0.1 µM calyculin A (GIBCO-BRL), 0.1 mM 
dithiothreitol, 0.01 mg/ml each chymostatin, leupeptin, aprotinin, pepstatin 
and soybean trypsin inhibitor (Sigma, St. Louis, MO). Samples were then 
sonicated (two 5-s bursts on ice), centrifuged at 12 000×g for 15 min at 
4°C and either assayed immediately or frozen and stored at −80°C 
(Tombes et al., 1999). 
 
For figure 6.1 P4 O4 immunopanned cells were harvested for CaMKII 
activity assay immediately after immunopanning. Cells from DRG 
cocultures were harvested after DRG explants were incubated for 1 week 
post explant. ATX and lacZ was added at 0.1µg/ml for 1 hour incubated at 
37°C. 
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Figure 6.1: Premyelinating postmigratory oligodendrocytes express functional 
CaMKII. P4 O4 imunopanned rat oligodendrocytes express functional CaMKII. 
However, oligodendrocytes CaMKII activity is half of dorsal root ganglia neurons 
(DRG). However when DRGR cells cultures are incubated with ATX 0.1µg/ml or 
control LacZ 0.1µg/ml for 1 hour at 37°C before cells were harvested for activity 
assay  (Tombes et al., 1999).   oligodendrocytes N=2 DRG N=1. 
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Figure 6.2: Premyelinating postmigratory oligodendrocytes express functional 
CaMKII that responds to stimulation with autotaxin and T3. P4 O4 panned 
oligodendrocytes were plated on 0.1µg/µl fibronectin coated coverslips. (A) Cells 
were incubated for 1 day and then stimulated with either 0.1µg/µl autotaxin or 
control LacZ for 1 hour at 37°C before harvesting for CaMKII activity assay. Cells 
stimulated with ATX had greater kinase activity when compared to LacZ 
stimulated cells. N=2 (B) Oligodendrocytes treated with differentiation media 
containing N2T3 had higher kinase activity compared to cells treated with 
mitogens PDGF/FGF N=2 
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Inhibition of CaMKII alters MBP expression in zebra fish 
 
Treating fish with 10µM KN-93 for 24 hours alters the expression of MBP mRNA 
in the hind brain but not the posterior lateral line of 72 hour zebra fish. Fish 
treated in 35mm dish with a final concentration of 10µM KN-93, KN-92 or DMSO. 
Ran institu hybridization for MBP to detect altered MBP expression. 
 
Protocol for insitu hybridization 
 
 
 
Zebrafish Whole Mount In Situ Hybridization 
(NBT/BCIP detection) 
________________________________________________________________
____________ 
 
General embryo preparation: 
Stage embryos to desired age, anesthetize with MESAB (minimum 42ul/ml) and 
fix with 4% PFA in 1X PBS (new, never thawed)  O/N at +4C 
Wash embryos with 1x PBT 5min (x2) 
Quick wash embryos with 100% MeOH, then change to fresh 100% MeOH. 
Embryos can be stored in Methanol long term at -20C 
(If need to use embryos sooner, put in 100% MeOH at RT for 15min, then 
transfer to -20C for 2 hrs) 
 
Day 1 - All steps during day 1 should be RNase-free (using DEPC water) and are 
carried out at RT except when noted  
Rehydrate embryos through methanol/PBT series - discard in MeOH waste! 
 66/33, 33/66, 0/100: 10’ each wash shaking -1mL  
Wash with PBT 5min (x2) – 1mL 
Treat with proteinase K if older than 24hpf (do not freeze/thaw stock more than 
5x) 
 5µg/ml in PBT at 37C: 0.5min per hour age (ex. 30min for 60hpf) - 500uL 
Treat with ice-cold acetone 8min at -20C (or on ice) – 500µL 
Wash 1X PBT 5min x2 – 1mL 
Post-fix with 4% PFA in 1xPBS 20min – 500µL (discard in PFA waste!) 
Wash with PBT 5min x5 -1mL 
Incubate embryos in pre-warmed 1xHyb- at 65C 5min – 500µL - discard all Hyb 
mixes in formamide waste! 
Remove 1XHyb- and prehybridize in prewarmed 1xHyb+ for at least 1hr at 65C – 
500uL 
Dilute probe stocks: 1:100-1:300 in 1xHyb+ (if first time using) 
**Note:  is some cases, it is best to prehybridize a newly diluted probe with 
embryos for one night before doing the in situ, this can lower background 
Preheat probe to 65C  
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Aspirate prehybridization solution and replace with pre-warmed probe: 65C ~18 
hr (minimum 50-100uL probe per tube – make sure all embryos are suspended) 
 
Day 2  
Prewarm solutions below at 65C before using 
Remove diluted probe/hybridization solution and SAVE for re-use (use 200µL 
pipette tip) be sure to change tips when using different probes! 
Washes (500µL per tube) - use drawn out Pasteur pipette or 1mL pipette to 
aspirate 
Use 1mL volumes for all washes - Discard all solutions with Hyb mix in separate 
formamide waste! 
 
 1xHyb- (quick wash) (x1) 
 66% Hyb-/33% 2xSSC 10’ 65C (x1) 
 33% Hyb-/66% 2xSSC 10’ 65C (x1) 
 2xSSC 10’ 65C (x1) 
 0.2xSSC 20’ 65C (x2) 
 
 66% 0.2xSSC/33% 1xPBT 5’ RT (x1) 
 33% 0.2xSSC/66% 1xPBT 5’ RT (x1) 
 1xPBT 5’ RT (x1) 
 
Block:  Roche western blocking reagent 1:10 in 1XPBT for at least 1hr at RT on 
shaker – 500µL 
 
Dilute antibodies in blocking buffer: (500µL per tube)  
Note: do NOT use antibodies after they have expired!!! 
Anti-Dig-AP 1:10,000 
Anti-Fluorescein-AP 1:10,000 
 
Incubate in primary antibody O/N at 4C (lay tubes on side) 
 
Day 3 
Washes (all 1mL volume and on shaker) 
 1xPBT (quick wash) (x1) 
1xPBT 15’ RT (x6) 
1x coloration buffer + 0.1% Tween-20 5’ RT (x3) 
 
Coloration reaction:  1x coloration buffer + 0.1% Tween-20 + NBT/BCIP 
(4.5µL/3.5µL per 1mL of coloration buffer), let develop in dark and monitor signal, 
put at 4C or RT in eppendorf tubes for indicated times: 
 
ATX-dig   2 nights at 4C   Fli1-dig ~2hrs at RT 
MBP-dig 1 night at 4C   Foxa2-dig 1 night at 4C 
DM20-dig 1.5hrs at RT    Foxa2-fl 1 night at 4C 
Olig1-dig  1 night at 4C 
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Olig2-dig  1 night at 4C 
Sox10-dig 1 night at 4C+couple hrs @ RT 
 
Note for NBT/BCIP:  When solution gets older, it may precipitate out so heat to 
37C for a few minutes to put back into solution 
If first time using probe:  Monitor color reaction under dissection scope 
frequently! 
 
When coloration reaction completed: 
 Aspirate coloration solution 
 Quick was embryos with 1xPBT 
 Dehydrate in methanol to clear out background for a few minutes then 
store in fresh  methanol at -20C O/N up to a couple of months or minimum 
2hrs at RT 
 
Note:  fish may look slightly pink but this will disappear after addition of Methanol 
 
Rehydrate through methanol/PBT series then equilibrate in 90% glycerol/PBS for 
imaging  
Store at +4C 
 
Imaging 
Glue coverslips to both sides of a slide to create a space in between; mount fish 
in the space using 90% glycerol.  Move fish to desired position then place a long 
coverslip across the glued coverslips on each side.  Nailpolish the long coverslip 
to keep in place; slides can be stored at +4C temporarily 
 
Imaging fish from the side: mount fish using 2-3 coverslips on each side of slide; 
do not remove the yolk sacs.  3 coverslips works best for 36-48hpf fish; 2 
coverslips works well for 60-72hpf fish 
Imaging fish dorsally: remove yolk and mount fish with 2 coverslips on each side  
 
Fish can be imaged on Zeiss dissecting microscope in microscopy core using 
extended focus software 
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Solutions: 
 
PBT: 1X PBS + 0.1% Tween-20 
 
Hyb mix (store at -20C)  Hyb+   Hyb- 
Formamide   25 ml   25 ml  (+4C) 
20x SSC   12.5ml   12.5ml  (RT) 
Heparin, 25 mg/ml  0.1ml   -  (-20C In situ hyb reagent 
box) 
tRNA, 10mg/ml   2.5ml   -  (-20C In situ hyb reagent 
box) 
tween-20, 20%   0.25ml   0.25ml  (RT) 
citric acid, 1M   0.46ml   0.46ml  (RT) 
nuclease-free dH2O  9.19ml   11.79ml  (RT) 
    50ml   50ml 
  
Coloration buffer (store at RT) 
Tris-HCL, pH 9.5, 1M  5ml  
MgCl2, 1M   2.5 ml 
NaCl, 5M   1ml 
H2O    41.5ml    
    50ml 
-Add Tween-20 immediately before use: 
 Tween-20, 20% 5µl/ml 
 
NBT stock:  50mg NBT + 0.7ml dimethyl formamide anhydre (71.4mg/mL) store at -20C protected from light 
BCIP stock:  50mg BCIP + 1.0ml dimethyl formamide anhydre (50mg/mL) store at -20C protected from light 
 
Reagents needed:   
Methanol      Yeast RNA (Applied Biosystems/Ambion 
#AM7118) 
PBT       20X SSC (American Bioanalytical 
#AB1315601000) 
Proteinase K (Invitrogen #25530015)    Formamide (Fisher #BP227-500) 
4% PFA in PBS      Heparin (Fisher #AC41121-0010) 
Acetone       RNase-free dH2O 
Tween-20      1M Citric acid 
Roche western blocking reagent (Roche#11 921 673 001) 1M Tris-HCl, pH 9.5 
Anti-Dig-AP (Roche#11 093 274 910)   1M MgCl2 
Anti-Fluorescein-AP (Roche# 1 426 338)   5M NaCl 
NBT (Roche: 11 087 479 001)    50% Glycerol/ 1X PBS 
BCIP (Roche: 10 760 994 001) 
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Figure 6.3: Inhibition of CaMKII by KN-93 alters the expression of mbp mRNA. 
(A) Fish treated with 10µM of the CaMKII inhibitor KN-93, the control KN-92, or 
vehicle control DMSO for 24hrs. Fish when treated with KN-93 showed a 
significant decreased or absent mbp mRNA expression compared to the two 
controls. However, in treatment groups and control groups the PNS structure of 
the posterior lateral line was not effected. (B) Statistical and graphical 
representation of the different binned categories of expression of mbp. In KN-93 
treated fish absent or diminished mbp expression accounted for almost 90% 
(when taken together) of the fish seen in these groups. In the control groups, only 
5% had an absent or diminished phenotype. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
131 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
132 
Inhibition of CaMKII alters in vivo morphology of oligodendrocytes in the 
zebrafish spinal cord.  
 
Nkx2.2a: meGFP fish were treated with 10µM KN-93 or the control KN-92 for 24 
hours. Fish were then fixed with 4% PFA in 1X PBS (new, never thawed)  O/N at 
+4C. Washed embryos with 1x PBT 5min (x2). Mounted on slides with coverslip 
spacers and imaged on a Zeiss 510 multiphoton microscope with a 40x objective 
and niquist sampling. 
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Figure 6.4: Inhibition of CaMKII alters the morphology to a much simpler 
morphology of oligodendrocytes in the zebrafish spinal chord. Fish treated for 
24hrs with KN-93 or the control KN-92 were imaged at 72hpf. A distinct 
difference was noticed in the simplistic morphology in the KN-93 treated fish vs. 
the KN-92 fish. A li phenotype with thicker process (indicating myelin) was seen 
in the control vs. the treatment group with more immature looking cells that have 
a highly branched morphology but not myelinating. 
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Colocalization of DM20 positive cells with Camk2b1 in zebrafish ventral 
spinal cord.  
 
 
In situ hybridization on 72hpf zebrafish with dm20 probe and Camk2b1 probe. 
Insitu hybridization was performed then cryostat sectioning of fish embedded In 
OCT after cryoprotection was performed (20% sucrose ) were cut at 20µM and 
mounded on slides and imaged on Leica confocal microscope.  
 
Methods for double insitu hybridization.  
 
Zebrafish Whole Mount Double Fluorescent in situ Hybridization 
________________________________________________________________
____________________ 
Adapted from Julich et. al., 2005; Clay and Ramakrishnan, 2005;  
Brend and Holley, 2009; Jim Lister and Bruce Appel (3/14/06) lab protocols 
Update 6/8/10 
General embryo preparation: 
Stage embryos to desired age, anesthetize with MESAB (minimum 100ul/ml) and 
fix with 4% PFA in 1X PBS (new, never thawed) O/N at +4C 
Wash embryos with 1x PBT 5min (x2) 
Quick wash embryos with 100% MeOH, then change to fresh 100% MeOH. 
Embryos can be stored in Methanol long term at -20C 
(If need to use embryos sooner, put in 100% MeOH at RT for 15min, then 
transfer to -20C for 2 hrs) 
 
Probes:  Use both a Dig- and fluorescein-labeled probe; look at notes to decided 
which to use 
 
Day 1 - All steps during day 1 should be RNase-free (using DEPC water) and are 
carried out at RT except when noted  
Rehydrate embryos through methanol/PBT series 
 66/33, 33/66, 0/100: 10’ each wash shaking (1mL) 
Pre-treat embryos with 1% H2O2 in PBT 30min to inactivate endogeneous 
peroxidase activity (500µL) 
Fix in 4% PFA 20min – 500µL (discard in PFA waste!) 
Wash with PBT 5min (x2) – 1mL 
Treat with proteinase K if older than 24hpf (do not freeze/thaw stock more than 
5x) (500µL) 
 10µg/mL in PBT at RT: 30min (for 36hpf to 5dpf); 10min (18-somite to 
24hpf) 
Treat with ice-cold acetone 8min at -20C (or on ice) - 500µL 
Wash 1X PBT 5min x2 
Post-fix with 4% PFA in 1xPBS 20min – 500µL (discard in PFA waste!) 
Wash with PBT 5min x5 -1mL 
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Incubate embryos in pre-warmed 1xHyb- at 65C 5min – 500µL - discard all Hyb 
mixes in formamide waste! 
Remove 1XHyb- and prehybridize in prewarmed 1xHyb+ for at least 1hr at 65C – 
500uL 
Dilute probe stocks: 1:100-1:300 in 1xHyb+ (if first time using) 
**Note:  is some cases, it is best to prehybridize a newly diluted probe with 
embryos for one night before doing the in situ, this can lower background 
Preheat probe to 65C  
Aspirate prehybridization solution and replace with both pre-warmed probes 
together: 65C ~18hr (minimum 50-100µL probe per tube – make sure all 
embryos are suspended) also run single in situs on your experimental gene (see 
“controls” section at end of protocol) 
For negative controls for fluorescence do not add probes 
 
Day 2  
Prewarm solutions below at 65C before using 
Remove diluted probe/hybridization solution and SAVE for re-use (use 200µL 
pipette tip) be sure to change tips when using different probes! 
Washes (500µL per tube) - use drawn out Pasteur pipette or 1ml pipette to 
aspirate 
**Note:  Discard all solutions with Hyb mix in formamide waste 
 
 1xHyb- (quick wash) (x1) 
 66% Hyb-/33% 2xSSC 10’ 65C (x1) 
 33% Hyb-/66% 2xSSC 10’ 65C (x1) 
 2xSSC 10’ 65C (x1) 
 0.2xSSC 20’ 65C (x2) 
 66% 0.2xSSC/33% 1xPBT 5’ RT (x1) 
 33% 0.2xSSC/66% 1xPBT 5’ RT (x1) 
 1xPBT 5’ RT (x1) 
 
 
Block:  Roche western blocking reagent 1:10 in 1XPBT for at least 1hr at RT on 
shaker – 500µL 
(note:  antibodies should be preincubated for an hour before use – read below*) 
Antibodies:  Optimize which order the antibodies should be added for your 
probes – look at “notes” section below to optimize 
Dilute antibodies in blocking buffer (500µL) 
Anti-Dig-POD (HRP) 1:1000 
Anti-Fluorescein-POD (HRP) 1:500 
*Preincubate diluted antibodies in blocking buffer for at least 1hr before adding to 
embryos  
Incubate in antibody O/N at 4C (lay tubes on side and make sure all embryos are 
submerged) 
 
Day 3 (after TSA amplification all steps must be carried out in the dark) 
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Wash: 1xPBT (quick wash) (x1) - 1mL 
Wash: 1X PBT 15min (x6) – 1mL 
Prepare TSA/Cy3 or TSA/Fluorescein solution 1:50 in amplification reagent (spin 
down TSA substrate before using: 10,000rpm for 1min) and add to embryos for 
30-60min at RT (may need to optimize time for each probe) 
Try to use the least amount of volume possible! ~50µL per tube depending on 
how many embryos have; lay tubes on side, shake gently on orbital shaker and 
protect from light from this step on!!   
Wash: 1X PBT 15min (x6) – 1mL 
Block peroxidase activity of first antibody with 1% H2O2 in PBT 30min at RT - 
500µL 
Wash: 1X PBT 10min (x3) - 1mL 
Block for second antibody:  Roche western blocking reagent 1:10 in 1XPBT for at 
least 1hr at RT shaking - 500µL 
Preincubate antibodies in blocking buffer for at least 1hr before adding to 
embryos:  
Anti-Dig-POD (HRP) 1:1000 
Anti-Fluorescein-POD (HRP) 1:500 
Incubate in antibody O/N at 4C (lay tubes on side and make sure all embryos 
submerged) 
 
Day 4 
Wash: 1xPBT (quick wash) (x1) 
Wash: 1X PBT 15min (x6) 
Prepare TSA/Cy3 or TSA/Fluorescein solution 1:50 in amplification reagent (spin 
down TSA substrate before using: 10,000rpm for 1min) and add to embryos for 
30-60min at RT (may need to optimize time for each probe)    
Try to use the least amount of volume possible! ~50µL per tube depending on 
how many embryos have; Lay tubes on side, shake gently on orbital shaker 
Wash: 1X PBT 15min (x6) – still protect from light! 
 
 
Nuclear stain (2 options) 
1. (TO-PRO-3 iodide 642/661) (protect embryos from light at all steps) 
Notes:  Fish get very sticky during this stain so be very careful to not get them 
stuck into the pipette tip!! 
Wash embryos with 2xSSC 5min (x2) at RT 500µL 
Incubate in RNase 100µg/mL in 2x SSC (+0.1% Tween-20) for 30min at 37C 
(50µL per tube) 
 (Stock solution of RNaseA is 10mg/mL) 
Wash with 2X SSC 3min (x6) at RT - 500µL 
Add TO-PRO-3 at 33µg/mL in 2x SSC for 20-30min at RT (50µL per tube) 
 (Stock solution is 671.42µg/mL) 
Wash 2X SSC 3min (x6) - 500µL 
Fix with 4% PFA 20min at RT - 500µL 
Wash with PBT 5min (x2) – 1mL 
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2. Hoecsht (BisBenzimide H 33258) UV 346/460nm (intercalates A-T regions of 
DNA) 
Incubate with Hoechst 33258 (1µg/mL) in ddH2O 10min at RT 
Wash with 1X PBS 5min (x2) 
Wash with ddH2O 5min (x1) 
 
Clear O/N in 90% glycerol/PBS at -20C (it is easier to deyolk fish after the 
embryos have cleared O/N) 
 
Imaging 
Glue coverslips to both sides of a slide to create a space in between; mount fish 
in the space using Vectashield.  Move fish to desired position then place a long 
coverslip across the glued coverslips on each side.  Nailpolish the long coverslip 
to keep in place; slides can be stored at -20C temporarily 
 
Imaging fish from the side: mount fish using 2 coverslips on each side of slide; 
the yolk sacs do  not have to be removed.  Can be imaged using lower 
objectives (10x and 20x) 
 
Imaging fish dorsally: remove yolk and mount fish with 1 coverslip on each side 
(for higher objectives (40x and 63x) or can use 2 coverslips for lower objectives 
(10x and 20x) 
 
Note:  fish mounted with 1 coverslip on each side can be imaged using all 
objectives.  Fish mounted using 2 coverslips cannot be imaged on higher 
objectives because the objective pushes on the top coverslip and moves the fish 
 
Note:  yolk can cause background fluorescence 
 
If cutting fish with cryostat: 
 Fix with 4% PFA 20min, wash with PBT 5min (x5) 
 Soak embryos in 30% sucrose (in 1X PBS) at +4C until they sink and then 
leave an extra day or  2 (~1 week total) – protect from light! 
 Transfer fish to cryomold and fill with O.C.T. (be sure to remove majority 
of sucrose) 
 Transfer block to -80C to freeze and store in sealed bag at -80C 
 
 
 
 
 
 
CONTROLS – (must run these controls to make sure there is no unspecific 
overlap and that the antibodies are not binding unspecifically) 
1.  Single fluorescent in situs of both probes 
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2. Negative control:  do not add probes and continue with the protocol 
3.  Double fluorescent in situs without adding second antibody on day 3 
(leave in block solution  O/N) and continue with TSA amplification:  testing 
whether H202 is blocking HRP activity of first  antibody.  If it is not then you will 
see both green and red fluorescence (I have tested this and  the H2O2 has 
always quenched the first HRP!) 
 
NOTES:   
(From Brend and Holley, 2009) 
§ Fluorescein-labeled probes are weaker than dig-labeled probes, best to 
detect the fluorescein-labeled probe first 
§ If one of the genes is expressed at a low level, make a dig-labeled probe 
for the weak gene and detect it first 
§ TSA/Fluorescein should only be used with fluorescein-labeled probe, NOT 
dig-labeled probe! (use TSA/Cy3 for dig-labeled probe) 
§ Perkin Elmer TSA vs. Invitrogen Alexa TSA kits:  Most protocols use the 
Perkin Elmer kits, but if decide to use the Alexa-Tyramides, the buffer 
supplied does not work; they work only with the Perkin Elmer amplification 
diluent 
(From Clay and Ramakrishnan, 2005) 
§ Roche western blocking reagent consists of 10% casein protein in maleic 
acid buffer 
Sometimes can detect fluorescent background signal in the neuromasts and 
along the fin (Roche western blocking reagent minimizes the majority of the 
background but can still see sometimes). I have seen this with the ATX in situs 
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Solutions: 
 
PBT: 1X PBS + 0.1% Tween-20 
 
Hyb mix (store at -20C)  Hyb+   Hyb- 
Formamide   25 ml   25 ml  (+4C) 
20x SSC   12.5ml   12.5ml  (RT) 
Heparin, 25 mg/ml  0.1ml   -  (-20C In situ hyb 
reagent box) 
tRNA, 10mg/ml   2.5ml   -  (-20C In situ hyb 
reagent box) 
tween-20, 20%   0.25ml   0.25ml  (RT) 
citric acid, 1M   0.46ml   0.46ml  (RT) 
nuclease-free dH2O  9.19ml   11.79ml (RT) 
    50ml   50ml 
 
Reagents needed:   
Methanol      Yeast RNA (Applied Biosystems/Ambion 
#AM7118) 
PBT       20X SSC (American Bioanalytical 
#AB1315601000) 
Proteinase K (Invitrogen #25530015)    Formamide (Fisher #BP227-500) 
4% PFA in 1X PBS     Heparin (Fisher #AC41121-
0010) 
Acetone       RNase-free dH2O (DEPC) 
H2O2       1M Citric acid (Fisher #A940-500) 
Tween-20      90% Glycerol/ 1X PBS 
Roche western blocking reagent (Roche#11 921 673 001) Hoechst SAFC #B2883 
Anti-Dig-POD (HRP) (Roche#11 207 733 901)  O.C.T. 
Anti-Fluorescein-POD (HRP) (Roche#1 426 346)   
TSA Plus Fluorescein system (Perkin Elmer #NEL741001KT)  
TSA Plus Cyanine 3 system (Perkin Elmer #NEL744001KT)   
TO-PRO-3 iodide 642/661 (Invitorgen #T3605) 
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Figure 6.5: Double florescent Insitu hybridization of dm20 and camk2b1 mRNA. 
dm20 positive (green) cells are labeled in the ventral spinal cord of zebrafish 
along with the colocalized camk2b1 (red). First conformation that oligodendrocyte 
cells in the fish express camk2b. Bar. 10µm 
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Colocalization of active pCaMKII and O4 at the oligodendrocyte cell 
surface.  
 
 
Cells immunopanned from P3 rat pups and plated on fibronectin coated 
coverslips (0.1µg/µl) were fixed with 4% paraformaldehyde and blocked with 
DMEM 065 containing 10%FCS for 30 min. O4 was placed 1:1 with 
DMEM06510%FCS overnight at 4 degrees. Cells were then washed with PBS 
and Anti mouse igµ Alexa 594 was used to stain at 1:250 for 1hr at room 
temperature. Cells were washed with PBS and then probed with anit pCaMKII 
(upstate) 1:100 overnight at 4 degrees. Next day cells were washed with PBS 
and stained with alexa 488 anti rabbit at 1:250 for 1 hour at room temperature. 
Cells were washed with PBS and then mounted with vectashield on glass slides. 
Cells were imaged with the Zeiss 510 mutiphoton microscope 
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Figure 6.6: Positive active pCaMKII (green) immunestaining of O4 (red) positive 
OLG. Colocalization of active pCaMKII at the membrane surface along with the 
surface marker for premyelinating postmigratory oligodendrocytes. Scale bar: 
20µM. 
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Inhibition of CaMKII alters the expression of oligodendrocyte myelin 
markers but not early transcription factors.  
 
 
P3 A2B5 immunopanned oligodendrocytes were plated on 6 well plates 1million 
cells per well and treated with KN-93 or MyrAIP for 6 hours. KN-92 and a Control 
Myr Peptied were used as controls. Cell were allowed to sit for 24 hours and then 
treated for 6 hours at 10µm for each treatment. Once treatment of KN-93 or 
MyrAIP was over, cells were harvested for RNA using the qiagen MINI kit. RNA 
was measured and then DNAsed using the ambion turbo DNAse kit. cDNA was 
made from the treated RNA using omniscript. With the use of random hexomers. 
qRTPCR was performed on cDNA refer to protocol for quantitative approach and 
materials.  
 
Generate cDNA using Omniscript Reverse Transcription Kit (Qiagen) 
_____________________________________________________________________________
_____________ 
 
(For use with 50ng to 2µg RNA) 
 
-In separate PCR size tubes add RNA and RNase-free water to a total volume of 13µL.    
-Heat 65C for 5 min in thermocycler then place on ice immediately! 
-Make master mix: (recipe is for one reaction, multiply by number of samples running + 10% 
extra)  
All components come with kit except RNase inhibitor and OligodT: 
-RNase inhibitor – be sure to dilute to 10units/µL in Rnase-free dH2O (if comes at different 
concentration) 
-OligodT (Roche) comes as 40µg (8nmol) solid.  The stock is diluted in 80µL Rnase-free dH2O to 
100µM (500ng/µL).  The working stock is diluted 1:5 in Rnase-free dH2O to 20µM (100ng/µL). 
   
  +RT master mix     no RT master mix 
  2µL   Buffer RT   2µL 
  2µL   5mM dNTPs    2µL 
  1µL   20uM random Hexomers 1µL 
  1µL   10u/µL Rnase inhibitor  1µL 
  1µL   Omniscript RT   ----- 
  -----   dH20 (Rnase-free)  1µL 
 
-Vortex master mixes and spin down.  Place on ice until ready.   
-Add 7µL master mix to appropriate tubes (+ and – RT) – change tips in between samples! Final 
volume of reaction = 20µL 
-Incubate at 37C for 1 hour in thermocycler (make sure to put a +4C forever step at end)  
(Can stop here and leave cDNA at +4C for a day or two, do not store in freezer!!) 
 
 
qRT-PCR (using SYBR GREEN) – Fuss lab 
 
Before setting up your experiment, need to optimize primers: 
Note: Primer design: generate a ~100bp product 
Fluorescence with SYBR green has a linear relationship with DNA mass (make sure primers 
comparing generate same size product!! – or very similar) 
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1.   To determine annealing temp. of primers:  use end-point PCR (+ and - RT) and run on 
 agarose gel 
2. To determine primer efficiency:  Run standard curve – Use dilution series using RNA with 
 known expression:  2ng, 20ng, 200ng, 2ug  
 -The difference in the primer efficiency between the gene of interest and endogenous 
 control primer set should not exceed 5% 
 (More info under analysis section) 
  
Setup: 
1.   Make cDNA from RNA  
 We use Sensiscript RT kit (Qiagen) for small amounts of RNA (up to 50ng) and 
 SuperscriptII (Invitrogen) for more than that 
 
 -Determine amount of RNA to be used for your experiment from dilution series of primers   
 -Make enough to run duplicates of both +RT and no RT control (a single no RT control 
 can also be run) 
 -Add same amount of RNA to each cDNA reaction 
 -Ex. If using 2ng RNA per reaction and running 3 primers you will need 12ng RNA (2ng 
 x2duplicates x3primers) so start with about 20ng RNA for your + and –RT reactions 
  
 
2. Making the SYBR green master mix: 
 -The number of master mixes to make is the number of primers running 
 -Make one master mix for one primer set for all samples to be run with that primer; cDNA 
 will be added directly to wells separately after 
 -Make 10% extra of master mix 
 Ex. If have 4 samples to be run in duplicates, then will need to make a master mix for 8 
 wells: multiply each master mix component by 8.8 (make 10% extra so do not come 
 short).  This is done for each primer 
 
 SYBR green master mix comes as a 2X mix. (BioRad) 
 Each reaction is 50µl total volume 
  
 Master mix recipe for single reaction: multiply all reagents by x8.8 (from example above)  
 (a separate master mix needs to be made for each set of primers ) 
   
  SYBR green mix  25µl 
  Forward primer   x ul (0.15uM final)   
  Reverse primer   x ul (0.15uM final) 
  ddH2O (do not use DEPC!) x ul 
  cDNA*    x ul  
      50 ul total (look at example **) 
 *cDNA is not added to supermix, it is added to wells separately after master mix but need 
 to calculate its volume into the mix to determine how much ddH2O to add to get to a 
 total volume of 50 ul 
 
 **ex. If concentration of RNA used for cDNA reaction is 1ug/ul and using 2ng per 
 reaction, then 2ul of cDNA will need to be added per well and the total volume of the 
 master mix will be 48ul - that is the volume of master mix to be pipetted into wells.  
 NOTE:  It is suggested to add cDNA to master mixes for better reproducibility, but this 
 requires making a master mix for each sample – this is a lot of work depending on how 
 many samples you have.  We have had great reproducibility with duplicate samples by 
 pipetting cDNA directly into the wells and chose to continue to do it this way. 
 
 -Add master mix and samples to appropriate wells in strip 
  1. Number the tube strips first so that you do not mix them up!! 
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  2. Add master mix to appropriate wells in tube strips (48ul using example  
   from above**) 
  3. Add cDNA to appropriate wells separately– (change tips for each well!)  
   (add 2ul using example from above**) 
  4. Put strip caps on tubes and spin to collect liquid at bottom 
   
 -Protocol setup menu:  Click “edit” 
  Adjust conditions as necessary 
  Cycles:  95C 15min 
    94C 15sec 
     XC 20sec – annealing temp variable - depends on primers using 
    72C 20sec 
    Read Plate 
    Go to line #2 x 34 
    Melting curve 70C to 90C 
    END 
    No need to put a 4C step at end!! 
 
  Make sure that reaction volume = 50ul (top right of screen) 
 
 -When done setting up, put sample strips into thermocycler in Karen’s room and use 
 metal “thing” to push down all caps and make sure they are tightly on 
 
 
 
 
4. Analysis 
 -To compare single gene expression between different samples, analyze using the 
 comparative Ct method - remember that to run this analysis method, the difference in the 
 primer efficiency between the gene of interest and the endogeneous control primer set 
 should not exceed 5%) 
  
 Set fluorescence threshold to where all sample amplification curves are in their linear 
 (exponential phase) and record their CT values at this threshold.  Do not move the 
 threshold while recording numbers.  Note: the threshold value can be recorded and re-
 used if desired; the value is located in the quantitation section on the right side under the 
 threshold. 
 
 Equation: (note CT value is inversely proportional to expression) 
 ∆CT (Control sample) = (CT experimental gene) – (CT endogeneous control gene) 
 ∆CT (Experimental sample) = (CT experimental gene) – (CT endogeneous control 
 gene) 
 
 ∆∆CT = ∆CT (Control sample) - ∆CT (experimental sample) 
 2∆∆CT = fold increase or decrease of control (control will be 1; 20 = 1) 
 
 Refer to:  Livak KJ and Schmittgen TD 2001. Analysis of relative gene expression 
 data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 
 
 -Comparing expression of different genes within a single sample 
 Need primer efficiencies for this calculation since we are using the same sample for 
 the comparison, endogeneous normalizing controls do not need to be run (read below 
 under section “determining primer efficiencies” 
 Equation rationale: 
  Ro = RCT x (1+E)-CT 
   
 
 
 
 
 
149 
  Ro = starting fluorescence (proportional to starting template quantity) 
  RCT = Fluorescence at cycle CT is same for all samples so becomes a constant 
  E = Primer efficiency (100% = 1) 
  CT = Cycle at threshold T 
 
 Final equation to use: Ro = (1+E)-CT 
 Compare Ro values from all different primers  
 Refer to:  Peirson, et. al. 2003.  Experimental validation of novel and conventional 
 approaches to quantitative real-time PCR data analysis.  Nucleic acids research. 
 
 -Determining Primer efficiencies: (100% efficiency is doubling of product) 
 If did not already specify standards and their quantities when setting up protocol, go to 
 “master” and do it there. 
 Under quantification menu, select wells that are standards.  To the right of the plate click 
 “manage” and then select all wells using for curve and name it and exit.  Select that 
 newly made group then above quantitation curve, select log scale and move smooth all 
 the way to the left. 
 There is a graph to the right that will show Ct vs. log RNA.  Toggle axis so the x-axis is 
 the log RNA and y-axis is the Ct.  An equation will be displayed in form of y = mx + b     
 (m = slope); R2 value is also displayed which is a statistical term that says how good one 
 value is a predicting another value; if R2 = 1 then it is perfect; R2 value > 99% is good   
 
   Plug in slope into equation:  Efficiency = 10(-1/slope) – 1  
 
 (refer to website: http://www.uic.edu/depts/rrc/cgf/realtime/data.html) 
 Note: a 10-fold difference in sample is shown as 3.3 cycles in the log scale  
 (log2 10 = 3.3 or 23.3 = 10) 
 A slope of -3.3 in the graph (x-axis: log quantity; y-axis: Ct value) = 100% efficiency
 because every 3.3 cycles is a 10-fold (or log quantity of 1) change; slope = -3.3/1 
 Note:  recommended efficiency is between 90-100% and the slope between -3.1 and -3.6 
 
 -Comparing how much material between samples using Ct values: 
 Every 3.3 cycles is a 10-fold difference; log2 10 = 3.3 or 23.3 = ~10; log2 100 = 6.6 or  
 26.6 = ~100 
 
 -Comparing different runs: 
 -CT values generated from two different amplification runs can be directly compared only 
 if an identical FT (fluorescent threshold) is used for each run 
 -FT must be fixed if data from multiple runs are to be directly compared 
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Reagents/Supplies needed: 
 
§ Reverse transcriptase of choice - We use: Sensiscript (Qiagen #205211) – up to 50ng 
          SuperscriptII (Invitrogen #18064-014) 
 (Not included in the RT kits: you will also need an RNase inhibitor and either an OligodT 
 primer or random primers) 
 
§ SYBR green mix of choice - We use: BioRad iQ Supermix #170-8882 
 
§ Forward and Reverse Primers for both experimental and control genes (~100bp product) 
 
§ ddH2O autoclaved (not DEPC!) 
 
§ Flat cap strips – BioRad #TCS0803 
 
§ Low tube strips, white – BioRad #TLS0851 
 
§ qPCR machine  
 
 
Other considerations: 
 
§ Use filter-barrier pipette tips 
§ It is best to dilute template to between 2-10ul to avoid inaccuracies in pipetting low 
volumes 
§ Mix all reagents well prior to making reaction mixes (inversion then quick spin) 
 
Helpful reference papers: 
§ Nolan et. al. 2006.  Quantification of mRNA using real-time PCR.  Nature Protocols. 
§ Rutledge and Cote 2003.  Mathematics of quantitative kinetic PCR and the application of 
standard curves.  Nucleic Acids Research. 
 
Helpful websites: 
§ http://www.uic.edu/depts/rrc/cgf/realtime/data.html 
§ http://pathmicro.med.sc.edu/pcr/realtime-home.htm 
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Figure 6.7: Inhibition of CaMKII by alters the expression of oligodendrocyte 
myelin markers but not developmental transcription factors. Inhibition with either 
KN-93 or MyrAIP decreases the expression of mbp, early expression exon 2 
containing mbp, and PLP. However, there is no statistical reduction of the 
transcription factor olig2. Black bar =100% of control values.  N=3.  Oneway 
ANOVA P< 0.05 
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Knocking out CaMKIIβ alters myelin thickness but not over all numbers of 
myelinated axons or numbers of myelinated axons based on diameter in 
the ventral spinal cord.  
 
Camk2b-/- and Camk2bA303R mice (both in the F2 129P2-C57BL/6 background; 
van Woerden et al., 2009; Borgesius et al., 2011) were generated and bred at 
Erasmus University Medical Center. Spinal cord tissue was prepared and 
analyzed by light microscopy as previously described (Dupree et al., 1998, 
Marcus et al., 2006, Forrest et al., 2009). Used Nikon scope with 100x objective 
and imaged 4 different fields of view in the ventral spinal cord per animal per 
conditon. Used Image J to calcualte caliber and circularity.  
 
Protocol for determining axon caliber and circularity using Image J 
1. Open image in Imag J 
2. Make it an 8-bit (image, type, 8-bit) 
3. Threshold (contol, shift, T) ths is automatic threshold (works for most images  
 you can alter it form here if you want 
4.Set image to ive you area and Curcularity (analyse, set mesurments, click area 
and cirularity). 
5.Set meusments for analysis (Analyze, Analyze Particles 
 a. Min sixe: 46 pix (ciricle w/1µm diameter) 
b. Show: chose Outlines 
c. click Display resutls  
d. click exlcutde edge particles 
6. in your result box click edit, copy all 
7. Paste this into excel 
8. Delete all axons with a circularity of less than 0.4: Circularity should have 
come out as the C column ( A column is axon #, B column is Area) when you 
pasted the results into excel. Highlight that column click ‘sort ascending’  (AZê 
box next to the Sigma sign), then delete all axons until you hit 0.4 circularity 
9. Discount any ‘red areas’ that are not really axons that Image J picked up 
finding the corresponding axon# on the ‘outlines’ windo. Once you have already 
remove all axons the circularity less than0.4, highlight column A and click ‘sort 
ascending’. Now you can delete the corresponding axons you did not wan to be 
counted.  
Converting area (pixels to Diameter (µm) 
 Area (pixels  Diameter 
 46-183  1-1.9 
 184-413  2-2.9 
414-782  3-3.9 
 783-1150  4-4.9 
 1151-1796  5-5.9 
 1797- 2442  6-6.9 
 2443-3088  7-7.9 
 3089-3734  8-8.9 
 3734 +  9+ 
 
 
 
 
 
154 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.8: There is no statistical difference in the number of myelinated axons 
based on axon diameter after knock out of CaMKIIβ at a young or adult age. A. 
P21 camk2b-/- mice show no statistical difference in the number of myelinated 
axons when grouped by axon size. There is a trend towards a loss of large 
diameter axons in the KO group; however, this is not statistically significant. B. 
Same results seen in juvenile as in adult 56 day old mice that here is no total loss 
or loss based on axon diameter. C. Camk2bA303R mice show no difference in 
myelinated axon number when ca2+/ calmodulin is unable to bind allowing this to 
be a catalytically altered mutant. 
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